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ABSTRACT 
 
Monoamine oxidases (MAO-A and MAO-B) are important enzymes regulating the 
levels of monoaminergic neurotransmitters. Selective and irreversible MAO-B 
inhibitors such as L-deprenyl and rasagiline are clinically used for the treatment of 
psychiatric and neurological disorders. Positron emission tomography (PET) is a non-
invasive imaging technique which has widely been utilized to visualize the localization 
of MAO-B in monkey and human brains and thereby has been useful for studying 
neurodegenerative diseases and epilepsy. This thesis deals with the synthesis and 
evaluation of novel fluorine-18 labeled PET radioligands for detection of MAO-B 
activity.  
 
The present thesis demonstrates that nine fluorinated propargyl amines were 
synthesized and tested for inhibition of MAO-B. In order to label those compounds 
with fluorine-18 seven chloro-precursors and two sulphamidate-precursors were also 
synthesized by multi step organic synthesis.  Radiolabeling of six chloro-precursors 
with fluorine-18 was accomplished by a one-step nucleophilic substitution reaction. 
Radiolabeling of two sulphamidate-precursors with fluorine-18 was performed in two 
steps, compromising a nucleophilic substitution followed by the removal of the 
protecting group. The incorporation yield of the fluorination reactions varied from 40-
70%. The radiochemical purity was >99% and the specific radioactivities were in a 
range of 190-240 GBq/µmol at the time of administration. 
 
In vitro MAO inhibition and/or autoradiography (ARG) experiments demonstrated a 
high selectivity for MAO-B over MAO-A for five of the compounds namely 
[18F]fluorodeprenyl, [18F]fluororasagiline, [18F]fluoro-N,4-dimethyl-N-(prop-2-ynyl) 
pentan-2-amine, [18F]fluorodeprenyl-D2 and  [18F]fluororasagiline-D2. All five 
compounds were examined by PET and showed a high initial brain uptake in known 
MAO-B rich regions in cynomolgus monkey. [18F]Fluorodeprenyl showed a kinetic 
behavior similar to [11C]deprenyl where its fast irreversible binding to the enzyme 
renders the distribution of this radioligand in tissue limited by blood flow rather than 
the MAO-B enzyme concentration. [18F]Fluororasagiline and [18F]fluoro-N,4-dimethyl-
N-(prop-2-ynyl)pentan-2-amine showed continuous increase of the radioactivity 
throughout the PET measurement that might be an indication of a blood-brain barrier 
penetrating radiometabolite which might in turn complicate a reliable quantification. 
Only [18F]fluorodeprenyl-D2 and [18F]fluororasagiline-D2 showed fast wash-out from 
the brain and less accumulation in cortical and sub-cortical regions. Radiometabolite 
studies demonstrated that both deuterated analogues were more stable measured in 
monkey plasma when compared to the non-deuterated analogues. 
 
These results together suggest that both [18F]fluorodeprenyl-D2 and 
[18F]fluororasagiline-D2 may be improved PET radioligands and potential molecular 
imaging biomarker candidates for PET studies in neuroinflammation and 
neurodegeneration, accompanied with astrocyte activation. 
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LIST OF ABBREVIATIONS 
 
11C Radioactive, neutron deficient isotope of carbon 
13N Radioactive, neutron deficient isotope of nitrogen 
15O Radioactive, neutron deficient isotope of oxygen 
18F Radioactive, neutron deficient isotope of fluorine 
68Ga Radioactive, neutron deficient isotope of gallium 
AD Alzheimer’s disease 
ARG Autoradiography 
BBB Blood brain barrier 
Bmax Receptor density 
BP Binding potential 
Bq Bequerel, SI derived unit of radioactivity 
CNS Central nervous system 
CT Computed tomography 
Cyclotron Particle accelerator 
DAST Diethylaminosulfur trifluride 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
FAD Flavin adenine dinucleotide 
HPLC High performance liquid chromatography 
HRRT High resolution research tomography 
i.v. Intravenous 
IC Inhibitory concentration 
ID Injected dose 
In vitro "in flask" i.e. in the test tube 
In vivo "in life" i.e. in the organism 
Kd Dissociation constant 
Kryptofix 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo-[8.8.8] hexacosane-
K2.2.2 
LAD Lithium aluminium deutride 
LAH Lithium aluminium hydride 
LC-MS Liquid chromatography-mass spectrometry 
Lipophilic Non-polar, tendency to not dissolve in water 
LogP Logarithm of partition coefficient 
MAO Monoamine oxidase 
MeCN Acetonitrile 
MeV Mega electron volt 
MRI Magnetic resonance imaging 
NMR Nuclear magnetic resonence 
NMRI Naval medical research institute 
p.i. Post injection 
PBS Phosphate buffered solution 
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PD Parkinson’s disease 
PET Positron emission tomography 
ROI Region of interest 
RT Room temperature 
SA Specific radioactivity 
SN2 Bimolecular nucleophilic substitution 
T1/2 Half-life 
TAC Time activity curve 
THF Tetrahydrofuran 
UPLC Ultra performance liquid chromatography 
UV Ultraviolet 
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1 INTRODUCTION 
 
1.1 POSITRON EMISSION TOMOGRAPHY (PET) 
 
The development of science has made it possible to track and quantify the spatial 
distribution patterns and dynamics of radioactivity in a living organism over time. 
Positron emission tomography (PET) is one of the most powerful technologies for 
this purpose which utilizes positron-emitting nuclides as the radioactive source1-4. 
Even though PET is a relatively recent technology, the principle has been understood 
for half a century. The first commercial PET scanners were developed in the late 
1960's which were using analogue electronics to generate tomographic images. In the 
late 1970's more sensitive detectors and tomographic capabilities began to appear and 
by the mid-1990's, PET became an important medical diagnostic tracer technique 
based on the detection of positron annihilation radiation and the subsequent 
processing of raw data into an image5, 6. It allows the investigation of bio-chemical 
transformations of drugs or other molecules in living systems and thereby offers 
possibilities to study physiology, molecular biology, energy metabolism, and drug-
receptor or drug-enzyme interactions. This also allows the methods, knowledge, and 
interpretation of results from tracer kinetic assays used in the basic biological 
sciences to be applied to humans by the quantitative measurement abilities of the PET 
system. PET is therefore rapidly becoming a major molecular imaging modality with 
several applications in oncology7, neuroscience8, 9 and cardiovascular imaging10. 
The reason why PET is so successful is that it enables to study the physiological 
parameters at the chemical and molecular level. Conventional imaging techniques 
such as X-ray, CT scans, and magnetic resonance imaging (MRI) provide mainly 
anatomical information. PET can detect the presence of chemical and metabolic 
changes in disease states, such as cancer, independently of the anatomic or structural 
changes detected by conventional imaging. In oncology PET can help in 
differentiating benign from malignant processes based on differences in biological 
activity. In addition, whole body imaging with PET provides a means to examine all 
the organ systems in the entire body for both primary and metastatic diseases in one 
procedure.  
Moreover PET is important not only from the diagnostic point of view; it can also play 
an important role in the discovery and development of new drugs11-16. The drug 
development process is a time consuming and expensive process and unfortunately 
most of the candidate drugs fail in the final step i.e. in clinical studies. It is possible to 
perform clinical studies earlier using  PET microdosing concept17 in receptor 
occupancy studies and thereby to speed up the drug development process. 
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1.2 HOW DOES PET WORK 
 
The transfer of tracer methods from the basic biological sciences to humans with PET 
is made possible by the unique nature of the radionuclides used in PET to label 
compounds such as 11C (t1/2 = 20.4 min), 18F (t1/2 = 109.77 min), 15O (t1/2 = 2.04 min), 
and 13N (t1/2 = 9.97 min). These are the radioactive forms of the natural elements such as 
12C, 19F, 16O and 14N that emit radiation which will pass through the body for external 
detection. Natural substrates, substrate analogues, and drugs are labeled with these 
radio isotopes without altering their chemical or biological properties. As a 
consequence, a very small amount of the radiolabeled compound can be administered, 
which allows biochemical processes to be studied in vivo over time without perturbing 
the system. Due to the short half-life of the radionuclide, radiolabeling, purification, 
quality control and administration should be accomplished within a very short time. 
Therefore, the radionuclide is incorporated as late as possible in the synthetic route. The 
short half-life of the radionuclides enable a sufficient amount of statistical data to be 
collected during the PET scan while keeping the radiation dose to a minimum.  
 
The nuclei of the positron-emitting radionuclides are neutron-deficient and decay by 
the conversion of a proton into a neutron by the emission of a positron (β+) and a 
neutrino (υe). Carbon-11 or fluorine-18 has a short half-life and positron emission 
accounts for 99% of its decay.  
 
Figure 1. Principle of positron emission tomography (PET) exemplified by 11C to 11B decay18. 
 
The positron (β+) can travel up to a few millimeters in wet tissue before encountering 
its antiparticle, an electron (e-), causing an annihilation that generates two high-energy 
(511 keV) gamma ray photons, which are emitted in essentially opposite directions 
(Figure 1). The total positron and negatron energy is therefore 1.22 MeV, the sum of 
their equal rest mass energies (Eo511 keV0.511 MeV), and their total momentum is 
zero. PET is based on the annihilation coincidence detection (ACD) of the two collinear 
511 keV rays. The photons are detected in coincidence as they reach the scintillators, 
creating a burst of light that in turn is amplified by photomultipliers, giving rise to an 
electrical signal that can be further processed by computing program. Only signals that 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
3 
 
are detected in pairs within a few nanoseconds are considered to originate from the 
same radioactive decay; the single photon detections that result from scattering are 
ignored. The detectors in the PET camera are arranged in a ring around the object under 
study, allowing the location of the decay to be determined.  
 
1.3 DEVELOPMENT OF PET RADIOLIGANDS 
 
Development of PET radioligands specific for receptors or enzymes has made it 
possible to evaluate the density and pharmacological action of receptors or enzymes in 
the brain, in addition to the receptor occupancy of therapeutic drugs. The success of a 
PET radioligand largely depends on its use in the applied experiment. Although the 
development of PET radioligands has been carried out for more than three decades, at 
present only relatively few established radioligands are available for a small number of 
targets. The development of new PET radioligands is needed together with the 
increasing use of PET in medical and biomedical research. Advancement of 
radiochemistry is needed in order to meet the growing demand for labeled potential 
PET radioligands. The development of a new radioligand is a complex and 
multidisciplinary field which is associated with physics, radiochemistry, medicinal 
chemistry, biology, pharmacology, drug metabolism, mathematics and regulatory 
affairs. 
 
A successful radioligand for CNS PET studies must provide information which is 
suitable for quantitative analysis of the target. The outcome result of a PET experiment 
is usually the binding potential (BP) and a reliable quantitative analysis. In order to 
acquire those a radioligand is required to have some important properties12, 19, 20,21, 22 
such as a suitable binding affinity, selectivity and specificity, lipophilicity and brain 
penetration, specific radioactivity (SA), radiolabeling and metabolism. The most 
common obstacle in developing a new PET radioligand is the relatively small window 
of appropriate combinations of the above mentioned parameters.  
 
1.3.1 Binding affinity 
 
Binding affinity is expressed as the inverse equilibrium dissociation constant (Kd). 
Binding affinity is an important requirement for a radioligand to be successful because 
of the concentration of binding sites (Bmax) in the region of interest. A typically 
successful radioligand has subnanomolar affinity to the target of interest and Bmax 
should exceed the Kd of radioligands for good image contrast. A ratio of 5-10 between 
Bmax and Kd can be used as initial parameters for developing new PET radioligands23, 24. 
A low concentration of binding sites means the radioligand should have a high binding 
affinity. Quantification of a reversibly-binding ligand is generally preferable over an 
irreversible one25. 
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1.3.2 Selectivity and specificity 
 
The success of a PET radioligand is highly dependent on its appropriate 
pharmacodynamics properties, such as selectivity and specificity for the target. 
Selectivity and specificity of the radioligand for the binding site is a key factor that 
affects the degree of nonspecific binding which is a major challenge in the development 
of radioligands. Nonspecific binding occurs when the radioligand binds with a 
molecular target or tissue other than the site of interest which is a major challenge in 
the development of new radioligands and is often considered as the reason for the high 
failure rate of new radioligands26. 
 
1.3.3 Lipophilicity and brain penetration 
 
Lipophilicity is an important physicochemical property which influences a 
radioligand´s absorption, distribution, metabolism and elimination. It is expressed as 
the partition ratio of a compound in octanol/water or as the logP or logD value. 
Lipophilicity can be calculated theoretically or measured experimentally. The partition 
coefficient, P, is used for the neutral compound, whereas the distribution coefficient, D, 
is used for the sum of all micro-species (µ-species) for ionisable compounds. The 
distribution coefficient, D, is pH-dependent.  
 	

	  ([])/([])  !"	

	  (#[μ − !
!])/(#[μ − !
!]) 
 
Lipophilicity is the most important factor for a radioligand´s capacity to cross the lipid 
membranes which is essential for targets in the CNS22, 27, 28. The extent of the 
radioligand´s specific to nonspecific binding ratios can also be affected by lipophilicity. 
Furthermore high lipophilicity leads to high protein binding and reduces the delivery of 
the radioligand to the specific sites29. On the other hand radioligands with low 
lipophilicity have higher water solubility, faster clearance through the kidneys and low 
blood-brain barrier (BBB) penetration. However, in the brain, a moderate lipophilicity 
and high affinity are required to achieve high ratios of specific to nonspecific binding29. 
For a molecule to cross the BBB, relatively small molecular weight (<600 daltons) and 
moderate lipophilicity are required. The suitable logP for radioligand to cross the BBB 
is in between 1.5 and 3.530. BBB is well equipped with efflux pump P-glycoprotein (P-
gp) which functions to repel many unwanted or xenobiotic compounds. Therefore, 
radioligands which are substrates for P-gp are highly inhibited at the BBB and are 
unable to reach the target31, 32. In general, substrate behavior for P-gp is promoted by 
high lipophilicity, positive charge at pH 7.4 and multiple aromatic groups33.  
 
1.3.4 Specific radioactivity (SA) 
 
The term "specific radioactivity" (SA) is defined as the amount of radioactivity or the 
decay rate of a particular radionuclide per unit mass of the radionuclide which is 
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generally expressed as the radioactivity of the labeled compound divided by the molar 
amount of the compound (Bq/mol). SA is an important parameter to be considered for 
the development of PET radioligands. A high SA is necessary due to many biological 
factors such as limited amount of receptors, high binding affinity to the receptor, and 
risk of inducing pharmacological side effects. In particular, due to competition with the 
labeled compound for the same receptor, the presence of unlabeled compound may 
have a negative effect on the concentration of radioactivity in the target tissue. Hence, a 
high SA might be critical for providing a sufficient contrast in PET images between the 
target tissue and its surroundings. For example, in order to visualize extrastriatal D2 
receptors by the dopamine D2 receptor radioligand [11C]FLB 457 with picomolar 
binding affinity of 20 pmol/L, a SA higher than 110 GBq/µmol is required for data 
quantification34. The maximal theoretical SA can be calculated from the following 
equation:  
 &'  ƛN, (	ƛ  	 *	+,- )  
(ƛ = decay constant, N = Avogadro constant, T,-	= the half-life of the radionuclide) 
 
Theoretical SA only depends on the half-life of the radionuclide and not on time. The 
maximal theoretical SA for 18F is 6.3 × 104 GBq/µmol35, 36. The SA obtained in a 
labeling experiment is usually much lower than the theoretical value due to isotopic 
dilution which means that SA will be a function of time and exponentially decline with 
the half-life of the radionuclide. 
 
&'	()  	'()
/0*1,- 2  
 
Where A(t) = radioactivity at the time of measurement, t = time after radioactivity 
measurement, m = mass of the compound. 
 
1.3.5 Radiolabeling and metabolism 
 
The radiolabeling of radiopharmaceuticals to be applied in PET is a complicated and 
extremely challenging process. The main challenge of using short-lived PET 
radioisotopes is their short half-life which imposes severe time restrictions. Therefore, 
PET radiolabeling procedures are usually limited to one or two distinct chemical steps 
with the introduction of the PET radioisotope as late in the radiosynthesis as possible. 
Recent development of the micro-reactor technology for radiosynthesis has some major 
advantages such as purer products, higher yields, shorter reaction time than for 
corresponding batch reactions, and more benign reaction conditions37, 38. The labeling 
position is also a key consideration, and can pose mainly two significant challenges, 
such as: i) is it synthetically viable and ii) is it metabolically stable. [11C]CO can play 
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an important role for labeling with carbon-11 at different position due to the broad 
range of labelling chemistry available using [11C]CO39, 40. 
  
One of the main reasons for failure of PET radioligands for CNS is if a radiometabolite 
enters the brain. PET experiments cannot differentiate between emitted gamma rays by 
the parent radioligand and emitted gamma rays by a radiolabeled metabolite. If a 
radiolabeled compound is rapidly metabolized, the radiometabolites may affect the 
acquisition of data and the quantitative parameters derived from41, 42 a PET study. 
Labeling a molecule in different positions can provide important in vivo metabolic 
information which is useful in determining the best labeling position. One example is 
the serotonin 5-HT1A receptor radioligand [11C]WAY10063543. 
 
1.4 MONOAMINE OXIDASE (MAO)  
 
In 1928 an enzyme called tyramine oxidase that catalyzed the oxidative deamination of 
tyramine was first isolated by Mary Hare44. Later it was shown by Blaschko and co-
workers that this same enzyme also possessed the property to oxidize catecholamines45. 
To reflect the more general reactivity of this enzyme, a general name monoamine 
oxidase (MAO) was given by Zeller in 193846. This enzyme is mainly found as an 
integral protein in the outer membrane of mitochondria in most cell types in the body, 
neuronal and non-neuronal cells in the brain and in peripheral organs47. Two isoforms 
of the MAO enzyme were found and called "MAO Type A" (MAO-A) and "MAO 
Type B" (MAO-B) according to their biochemical and pharmacological properties48. In 
general, MAO-A selectively oxidizes the "neurotransmitter" monoamines such as 
epinephrine, norepinephrine and 5-hydroxytryptamine while MAO-B selectively 
oxidizes the monoamines such as benzylamine, phenylethylamine, methylhistamine, N-
acetylputrescine, MPTP, N-phenylamine, octylamine. Both MAO-A and MAO-B 
oxidize tyramine, tryptamine, kynuramine, 3-methoxytyramine and dopamine49. MAO-
B catalyzes the oxidative deamination of catecholamine neurotransmitters, generating 
hydrogen peroxide which can form highly reactive oxygen species due to the presence 
of hydroxyl radicals. In Alzheimer´s disease (AD) increased oxidative stress is 
attributed to the aberrant generation of reactive oxygen species, leading to 
neurodegeneration50. 
 
Scheme 1.  Schematic representation of the oxidative deamination of monoamines to the corresponding 
aldehydes by MAO 
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In humans MAO-A is mostly expressed in the placenta, the adipose tissue, the thyroid 
gland and the lung, whereas its expression in various parts of the brain is rather low. In 
contrast, MAO-B is dominantly expressed in various parts of the CNS such as the 
striatum, the hypothalamus, the prefrontal cortex, the amygdala and the spinal cord. 
Furthermore, the uterus, the kidney, the liver and the heart are also rich sources for 
MAO-B51. In the CNS, MAO-A is predominantly found in catecholaminergic neurons, 
whereas MAO-B is more abundant in serotonergic and histaminergic neurons as well as 
in astroglial cells52-54. In the human brain MAO-B constitutes up to ~70% of total brain 
MAO activity55-57. Cerebral MAO-B level increases with age and a further up regulated 
in the brains of e.g. AD patients. Because of its central role in neurotransmitters 
metabolism, MAO-B represents an attractive target in the pharmacological therapy of 
neurodegenerative diseases such as AD55,58, Parkinson’s disease (PD)59, depression60 as 
well as social anxiety61. 
 
Both MAO isoforms differ in their inhibition properties and can be inhibited depending 
upon the chemical structure or the relative concentrations of the inhibitor. MAO 
inhibitors were employed clinically in the 1950s. MAO-A is selectively inhibited by 
e.g. pirlindole and clorgyline which have found to be highly effective in the treatment 
of depression62. On the other hand MAO-B inhibitors are applied for the treatment of 
PD63 as well as for depression64. MAO-B inhibitors can be distinguished into two 
classes such as reversible inhibitors and irreversible inhibitors65.  
  
Reversible MAO-B inhibitors are structurally related to MAO-B substrates, and bind to 
the active site of the enzyme and are metabolized relatively slowly. On the other hand 
irreversible or “suicide” inhibitors initially bind to MAO-B in a reversible fashion, are 
then are oxidized by the enzyme to the active inhibitor, which covalently binds to the 
enzyme via the flavin adenine dinucleotide (FAD) cofactor, thus rendering it 
permanently unavailable for amine metabolism66. L-deprenyl was the first compound 
identified as an irreversible MAO-B inhibitor and has 150-folds more potency over its 
D-isomer67, 68. More recently investigated MAO-B inhibitors such as rasagiline69, and 
mofegiline70 show irreversible binding properties whereas lazabemide71-73 shows a 
reversible binding property and milacemide74 shows partially reversible binding 
property.        
 
1.5 MAO-B PET RADIOLIGANDS 
 
The PET technique has been applied as an useful tool for imaging brain MAO-B 
activity in humans for studying neurodegenerative diseases75 and epilepsy76. Till now a 
number of selective and reversible or irreversible radioligands have been developed 
(Figure 2) in order to study MAO-B activity and density by PET77-79. For example 
[11C]deprenyl80, 81, [11C]pargyline82, [11C]deprenyl-D283, 84,  [11C]MD23025485, DL-4-
[18F]fluorodeprenyl86 and 6-[18F]fluoro-N-methyl-N-(prop-2-yn-1-yl)-hexan-1-amine87 
showed irreversible binding properties for imaging MAO-B, whereas [11C]SL25.118888 
and [18F]Ro43-046389, 90 indicated more reversible binding properties. A reversible 
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binding MAO-B radioligand might have advantages over the irreversible one due to its 
faster wash out from the brain.  Among those radioligands only carbon-11 labeled 
compounds such as [11C]deprenyl81 and [11C]deprenyl-D284, 91 were demonstrated as 
useful PET radioligands for assessing MAO-B in the human brain. MAO-B substrate 
N,N-dimethylphenylethylamine (DMPA) was labeled with carbon-11 at two different 
positions and used to measure the MAO-B activity in monkey brain92. So far no 
successful fluorine-18 labeled PET radioligand has been validated for clinical use. 
Therefore, there has been much interest in the development of fluorine-18 labeled 
MAO-B inhibitors as biological probes to map MAO-B activity.  
 
 
 
Figure 2. Structures of MAO-B PET radioligands: i) [11C]deprenyl, ii) [11C]pargyline,  iii) [11C]deprenyl-
D2, iv) [11C]SL25.1188, v) [11C]MD230254, vi) DL-4-[18F]fluorodeprenyl and vii) 6-[18F]fluoro-N-
methyl-N-(prop-2-yn-1-yl)- hexan-1-amine, viii) [18F]Ro 43-0463. 
 
 
1.6 STRATEGIES OF 18F-LABELING 
 
Fluorine is widely introduced in pharmaceutical compounds despite an unusual natural 
occurrence in biological molecules93. Although the introduction of a fluorine atom in a 
molecule generally modifies the physical and biological properties94, a large number of 
molecules exist where hydrogen was replaced by fluorine and the new molecules 
retained comparable properties95. [18F]Fluoride is one of the most widely used 
radionuclides in PET. Its convenient half-life (T1/2 = 110 min), β+ emitting decay mode, 
low positron energy (0,63 MeV), low radiation dose, short ranges in tissue and the 
possibility to distribute to the site that doesn’t have onsite cyclotron support it to be a 
suitable radionuclide for use in PET. [18F]Fluoride can be introduced to the radioligand 
by both nucleophilic and by electrophilic substitution. However, only nucleophilic 
[18F]fluoride fluorination was used in the work described in this thesis. 
 
1.6.1 Electrophilic radiofluorination 
 
For electrophilic radiofluorination reactions, [18F]fluorine gas ([18F]F2) is used as 
electrophile. [18F]F2 gas is produced via the nuclear reaction 20Ne(d,α)18F and is 
liberated from the cyclotron with [19F]F296.  As a result, the 18F/19F ratio is quantified as 
SA. Therefore, SA of electrophilic [18F]fluorine is in general low and not optimal for 
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synthesizing high SA 18F-labeled radiopharmaceuticals. When [18F]F2 is used for 
electrophilic substitution, the maximum achievable radiochemical yield is 50% because 
only one of the fluorine atoms in [18F]F2 is labeled with [18F]F.  
 
However, in 1997, Solin et al. developed a method to generate [18F]F2 with a higher SA 
upto 55 GBq/µmol than what is common for [18F]F2 upto 2 GBq/µmol97. In this 
approach 18F-labeled methyl fluoride ([18F]CH3F) is synthesized from [18F]F- aq(-).  
Then [18F]CH3F is flushed with neon gas in a quartz discharged chamber containing a 
variable amount of F2 where an exchange of F-18 for F-19 takes place. Applying this 
method, recently, Gouverneur succeeded in synthesizing [18F]F-TEDA, an electrophilic 
18F-fluorination reagent more useful and selective than [18F]F298. Generally, [18F]F2 is 
converted into less reactive and more selective [18F]fluorination agents99.   
 
Historically most early 18F labeled tracers were synthesized via the electrophilic path 
way such as [18F]FDG100 and then nucleophilic pathways were developed to obtain 
higher radiochemical yield with higher specific SA101. Despite the lower radiochemical 
yield and lower SA, electrophilic fluorination is still used today in the production of 
PET radioligands, e.g. [18F]F-DOPA102. Electrophilic fluorination was not considered 
in the current thesis work. 
 
1.6.2 Nucleophilic radiofluorination 
 
Nucleophilic substitution is a chemical reaction involving the addition of a nucleophilic 
molecule/atom into a molecule with a leaving group. As a result, the nucleophilic 
molecule forms a covalent bond with the parent molecule by displacing the leaving 
group via SN2 mechanism. In nucleophilic radiofluorination, [18F]fluoride ion is the 
nucleophile. 
 
The [18F]fluoride ion is prepared by the nuclear reaction 18O(p,n)18F in aqueous 
environment. In an aqueous environment, negatively charged ions must be 
accompanied by positively charged counter ions. [18F]Fluoride is washed out from the 
cyclotron target with traces of metal ions (counter ions) from the surface of the target. 
Nucleophilic [18F]F-  fluorination is also very sensitive to the presence of metal-ion 
traces formed by irradiation of the target103. Therefore, [18F]fluoride ion is isolated by 
passing through a light QMA Sep-Pak column where [18F]fluoride is retained by an 
ion-exchange reaction and allow the 18O-water as well as the metal ions to flow 
through. The retained [18F]fluoride ion is then eluted with an acetonitrile solution of 
Kryptofix and potassium carbonate 104, 105. Potassium carbonate and Kryptofix 2.2.2 are 
commonly used as counter ion and a phase-transfer catalyst. 
  
Fluorine has high hydration energy and the fluoride ion is a poor nucleophile in 
aqueous media. Therefore nucleophilic substitution reactions involving [18F]fluoride 
ion requires strict exclusion of water. The advantage of using acetonitrile as the eluting 
solvent is that it forms an azeotropic mixture with water. Evaporation of the acetonitrile 
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in a nitrogen atmosphere will remove any residual 18O-water105 simultaneously. The 
classical “rule” is that increased dryness will increase the reactivity of the [18F]fluoride 
ion. There are however numerous aliphatic reactions, that withstand relatively large 
amounts of water without influencing the radiochemical yield (RCY)106. Nucleophilic 
substitution with [18F]fluoride generally occurs by heating the dried residue of the 
K+[18F]fluoride-K222 complex with the precursor in a polar aprotic solvent such as 
acetonitrile, DMSO and DMF107. Currently, the use of certain polar protic solvents has 
been applied successfully in several examples108-110. 
 
In general nucleophilic substitution with [18F]fluoride is divided into aliphatic and 
aromatic substitution reactions. The aliphatic substitution reactions proceeds via a 
SN2 mechanism, using common leaving groups such as sulfonic acid esters (e.g. 
triflates, tosylates , mesylates or sulphamidate) or halides (Cl, Br or I). The choice of 
leaving group depends mainly on the stability of the precursors, the purification of the 
18F-labeled product and the potential for formation of byproducts111.   
 
Nucleophilic aromatic substitution with [18F]fluoride is the synthesis of aryl 
[18F]fluorides112. A prerequisite, is that the aromatic ring needs to be activated by the 
presence of one or more electron-withdrawing groups such as nitro-, cyano-, 
carbonyl-, positioned at ortho- or para- to the leaving group112. There are several 
possible alternatives for leaving groups but mostly a halogen, nitro or 
trialkylammonium group is substituted113, 114. A recent study shows that the 
diphenyliodonium (Ar-I+-Ar') group has an advantage over the presence of unnecessary 
electron withdrawing groups on the ring, but problems are associated with undesired 
radioactive byproducts115.  
 
A simple isotopic substitution, 18F for 19F, shows in general high radiochemical yield. 
However, the lower specific activity from these isotopic substitutions makes this 
process less practiced. 
 
All the fluorination reactions described in this thesis proceeded via SN2 mechanism in 
which either a chloride or a sulphamidate group was substituted by [18F]F- followed in 
some cases by the removal of a protecting group. 
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2 AIMS 
 
The overall aim of this thesis was to develop fluorine-18 labeled PET radioligands for 
imaging MAO-B. 
 
The following specific aims were set to meet the main objective: 
 
(i) To synthesize the precursors and reference standards  
 
(ii) To develop efficient synthetic methods for labeling the target compounds 
with fluorine-18  
 
(iii) To evaluate their binding to MAO-B in vitro and in vivo as well as to study 
the metabolic stability of the parent compounds measured in monkey blood 
plasma. 
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3 EXPERIMENTALS AND METHODS 
 
A brief summary of the general experimental and methods used during this thesis work 
are described here. 
 
3.1 CHEMISTRY 
 
3.1.1 Instrumentation and purification 
 
1H NMR spectra were referenced internally on CDCl3 (δ1H 7.26) and 13C NMR spectra 
were referenced internally on CDCl3 (δ13C 77.20). Liquid chromatographic analysis 
(LC) was performed with a Merck-Hitachi gradient pump and a Merck-Hitachi, L-4000 
variable wavelength UV-detector. A µ-Bondapak C-18 column (300 X 7.8 mm, 10 µm; 
Waters instruments) was used with a flow of 2 mL/minutes. LC-MS was performed 
using a Waters Quattra-ToF Premier micro mass spectrometer, or Waters SQD 3001 
single quadrupole mass spectrometer, coupled to Waters Acquity UPLC instruments. 
The ionization mode used was electro spray positive ionization (ESI+). Analytical TLC 
was carried out on 0.25 mm silica gel plates.  
 
Purification was not necessary in some cases and for certain cases, the compounds were 
purified by crystallization or distillation. In other cases, the compounds were purified 
by flash column chromatography, using prepacked silica gel cartridges, e.g. from 
Separtis such as Isolute® Flash silica gel or Isolute® Flash NH2 silica gel in 
combination with e.g. a FlashMaster II autopurifier (Argonaut/Biotage) and eluents 
such as gradients of hexane/EtOAc or pentane/diethyl ether. In some cases, the 
compounds were purified by preparative HPLC using a Waters auto purifier equipped 
with a diode array detector and/or on-line electrospray ionization mass spectrometer in 
combination with a suitable prepacked reverse phase column and eluents such as 
gradients of water and acetonitrile which may contain additives such as trifluoroacetic 
acid or aqueous ammonia. 
  
All solvents and chemicals were obtained from commercial sources and used without 
further purification. Purity of all synthesized compounds was ≥95% and was 
determined by NMR, HPLC, UPLC and LC-MS. 
 
3.1.2 General procedures for the synthesis 
 
3.1.2.1 Reduction by lithium aluminium hydride or lithium aluminium deuteride  
 
To a solution of starting material in dry THF, lithium aluminium hydride (LAH) or 
lithium aluminium deutride (LAD) (1M in THF) was added dropwise at -5°C. The 
reaction mixture was refluxed overnight and cooled to -5°C. Unreacted LAH was 
quenched with aq  NaOH and the mixture was stirred at RT for additional 30 minutes. 
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The reaction mixture was filtered and the filter cake was washed with diethyl ether (50 
mL). The filtrate was dried over MgSO4 and solvent was removed under reduced 
pressure to obtain the final product. The product was analyzed by NMR and LC-MS 
and used in the next step without further purification.   
 
3.1.2.2 Synthesis of intermediate propargyl amine 
  
To a solution of crude secondary amine in dry THF, K2CO3 was added and stirred at 
RT for 30 minutes. To the stirred solution propargyl bromide was added dropwise and 
the reaction mixture was stirred overnight at room temperature (RT), diluted with water 
and extracted with CH2Cl2 (3 x 50 mL).  The organic phase was separated followed by 
washing with saturated NaHCO3 and brine. Collected organic phases were dried over 
MgSO4 and filtered. The solvent was removed under reduced pressure to obtain the 
crude product as light yellow oil. The crude product was purified by silica-gel column 
chromatography.  Final product was obtained as oil and was analyzed by NMR, HPLC 
and LC-MS.  
 
3.1.2.3 Synthesis of (1,1-2H2)3-bromoprop-1-yne (deuterated propargyl bromide) 
 
To the stirred solution of (1,1-2H2)prop-2-yn-1-ol in dichloromethane at -5°C under 
nitrogen, phosphorus tribromide (PBr3) was added dropwise. The solution was stirred at 
that temperature for one hour followed by stirring additional three hours at RT. The 
reaction mixture was quenched at 0°C with H2O. The organic layer was washed 
successively with saturated NaHCO3 and H2O and dried over MgSO4. The solvent was 
allowed to evaporate carefully and the final product was obtained as colorless oil and 
was analyzed by NMR. The product was considered pure enough for the next step 
without further purification. 
 
3.1.2.4 Synthesis of chloroprecursors 
 
A mixture of intermediate propargyl amine and triethyl amine or pyridine in THF was 
stirred at RT for 30 minutes. To the stirred mixture mesyl chloride was added drop wise 
at -7°C and the reaction mixture was stirred at RT for additional 30 minutes. Saturated 
aqueous Na2CO3 solution was added and stirred for an additional 30 minutes. The 
organic layer was partitioned between CH2Cl2 and water. The organic phase was 
separated and washed with saturated NaHCO3 solution and brine followed by dried 
over MgSO4 and filtered. The solvent was removed under reduced pressure to obtain 
the crude product as light yellow oil. The crude product was purified by silica-gel 
column chromatography and final product was obtained as light yellow oil. The product 
was analyzed by NMR, HPLC and LC-MS. The final product was a mixture of two 
isomers.  
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3.1.2.5 Synthesis of fluorinated reference standards 
 
To the stirred solution of propargyl aminoalcohol in dichloromethane, diethylamino 
sulfurtrifluoride (DAST) was added dropwise at -5°C and the reaction mixture was 
stirred for 20 minutes at the same temperature. Saturated Na2CO3 solution was added to 
quench unreacted DAST. The organic layer was partitioned between CH2Cl2 and water. 
The organic phase was separated and washed with brine and dried over MgSO4 
followed by filtration. The solvent was removed under reduced pressure to obtain the 
crude product as light yellow oil. The crude product was purified by silica-gel column 
chromatography and gave the final product. The product was analyzed by NMR, HPLC 
and LC-MS. 
 
3.1.2.6 Synthesis of fluororasagiline 
 
To a solution of intermediate sulphamide in a mixture of DMF and tert-butanol, cesium 
fluoride was added, and the resulting mixture was stirred at RT for 60 hours. All 
volatiles were then removed in vacuo, followed by addition of 4N hydrochloric acid 
and ethanol to the residue. The resulting mixture was stirred at 80°C for 1.5 hours, 
allowed to cool to RT, and then partitioned between EtOAc and saturated aqueous 
Na2CO3. The aqueous layer was extracted with ethyl acetate and the combined organic 
layers were washed with brine, dried over MgSO4, and allowed to evaporate. The 
residue was purified by column chromatography on silica gel (EtOAc in hexane 0% → 
40%) to give the desired product. Highly purified material was obtained by short-path 
distillation of an aliquot using a Kugelrohr distillation apparatus to give a colourless, 
crystalline solid upon cooling to RT. The product was analyzed by NMR, HPLC and 
LC-MS. 
 
3.2 RADIOCHEMISTRY 
 
Fluorine-18 fluoride ([18F]F-) was produced from a GEMS PET trace cyclotron using 
16.4 MeV protons via the 18O(p,n)18F reaction on 18O enriched water ([18O]H2O). 
[18F]F- was isolated from [18O]H2O on a preconditioned SepPak QMA light anion 
exchange cartridge and subsequently eluted from the cartridge with a solution of 
K2CO3, Kryptofix-2.2.2 (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo-[8.8.8]hexaco 
sane-K2.2.2) in water (18 MΩ) and MeCN to a reaction vessel105. The solvents were 
evaporated at 160°C for 10-15 minutes under continuous nitrogen flow to form a dry 
complex of [18F]F-/K+/K2.2.2 and the residue was cooled to RT. The chloro or 
sulphamidate precursors in DMSO were added to the dry complex of [18F]F-
/K2CO3/K2.2.2. The closed reaction vessel was heated at 120-130°C for 10-20 minutes 
and cooled down to RT. For deprotection HCl was added to the reaction mixture and 
heated at 110°C for 10-20 minutes. The reaction mixture was cooled to RT and was 
diluted with water to a total volume of 2 mL before injecting it into the HPLC for 
purification. All fluorine-18 labeled radioligands were purified by reverse phase HPLC 
and MeCN-H3PO4 (0.01 M) was used as the eluting solvent. The elute was monitored 
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by a UV absorbance detector (λ = 214 nm) in series with a GM tube radioactivity 
detector. The fraction of the desired compounds was either collected, followed by being 
evaporated to dryness or was diluted with water followed by isolation with SepPak 
tC18 plus cartridge. The residue was dissolved in sterile phosphate buffered saline 
(PBS; pH = 7.4; 10 mL) and filtered through a sterile filter (0.22 µm; Millipore, 
Bedford, MA), yielding a sterile and pyrogen-free (< 1.25 EU/mL) solution of the 
radioligand. 
 
The radiochemical purity of all radioligands was determined by a reverse phase HPLC 
on a µ-Bondapak C-18 column (300 X 3.9 mm, 10 µm; waters instruments). The elute 
was monitored by a UV absorbance detector (λ = 214 nm) in series with a radioactivity 
detector (β-flow; Beckman, Fullerton, CA). The stability and radiochemical yield was 
tested with HPLC and TLC on silica gel (100% EtOAc was used as the eluting 
solvent). TLC plate was scanned with an AR-2000 Imaging Scanner and analyzed with 
Winscan 2.2 software. 
 
3.3 DETERMINATION OF MAO INHIBITION 
  
Human recombinant MAO-B and MAO-A enzymes prepared from insect cells were 
purchased from Sigma. The assays were designed to determine the inhibition of 
kynuramine oxidation in the presence of the compounds of interest according to a 
previously described methods116. The assays were designed to determine the generation 
of 4-OH-quinoline from kynuramine in the presence of the compounds of interest. A 
calibration curve of 4-OH quinoline (Sigma) was determined at λEx=310 nm/ λEm=400 
nm and used for calculation of the enzyme activity at the respective compound 
concentration. This relation was plotted and the IC50 was determined using the software 
GraFit 5 (Version 5.0.6). The assays were performed as follows. The compounds were 
diluted 1:2 in each step in 50 mM PBS (pH 7.4) so that a concentration curve between 
0.49 nM and 1000 nM was generated to determine the IC50 for MAO-B and between 
0.98 and 2000 nM for determination of inhibition of MAO-A, respectively. 
Kynuramine hydrobromide at a concentration of 125 µM for MAO-B and 100 µM for 
MAO-A, respectively, and 2.5 U/mL enzyme were added and the reaction followed 
measuring the absorption at 360 nm in a 5 minutes interval over 30 minutes at 37°C. 
The 30 minutes time point was used to determine IC50 values. As internal standards for 
MAO-B, pargyline and L-deprenyl and for MAO-A clorgyline were used. 
 
3.4 IN VITRO AUTORADIOGRAPHY 
  
Human brains without pathology were obtained from the Department of Forensic and 
Insurance Medicine, Semmelweis University, Budapest and the brains had been 
removed during forensic autopsy (control brains)117, 118. The post mortem time of the 
human brains was up to 11 hours until which the cadaver was stored at ±0°C. After 
removal, the brain was kept at -85°C until sectioning and then the whole hemisphere 
brain slices were kept at -25°C until the autoradiographic procedure began. Ethical 
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permissions were obtained from the relevant Research Ethics Committee of the 
respective institution. The sectioning of the brains and the autoradiography experiments 
were performed at the Department of Clinical Neuroscience, Karolinska Institutet. The 
sectioning was carried out by a Leica cryomacrocut system, yielding coronal or 
horizontal slices of 100 µm thickness.  
 
The autoradiographic procedures were identical with those used in previous studies119. 
The whole hemisphere sections were incubated for 90 minutes at RT with 4 MBq/200 
mL of the corresponding radioligand in  50 mM TRIS buffer pH 7.4 containing sodium 
chloride (120 mM), potassium chloride (5 mM), calcium chloride (2 mM) and albumin 
(0.1 % w/v). After incubation, the sections were washed in the same buffer three times 
for five minutes each time at RT, briefly dipped in ice cold distilled water, dried and 
exposed to phosphorimaging plates. The readings were made in a Fujifilm BAS-5000 
phosphorimager. Standards were prepared by serial dilution of the radioligand stock 
solution in assay buffer, using the phosphorimager’s Multi Gauge 3.2 image analysis 
software (Fujifilm). Blocking experiments were performed with 10 µM L-deprenyl, 
rasagiline and pirlindol, respectively. 
 
3.5 PET IN NON-HUMAN PRIMATE 
 
Cynomolgus monkeys (Macaca Fascicularis) were supplied by the Astrid Fagraeus 
Laboratory of the Swedish Institute for Infectious Disease Control (SMI), Solna, 
Sweden. The study was approved by the Animal Ethics Committee of the Swedish 
Animal Welfare Agency and was performed according to “Guidelines for planning, 
conducting and documenting experimental research” (Dnr 4820/06-600) of the KI as 
well as the “Guide for the Care and Use of Laboratory Animals”120. Anesthesia was 
induced by repeated intramuscular injections of a mixture of ketamine hydrochloride 
(3.75 mg/kg/h Ketalar® Pfizer) and xylazine hydrochloride (1.5 mg/kg/h Rompun® 
Vet., Bayer). The head of the monkey was fixed during the PET experiments121. Body 
temperature was maintained by Bair Hugger-Model 505 (Arizant Health Care Inc., 
MN, USA) and monitored by an oral thermometer. ECG, heart rate, respiratory rate and 
oxygen saturation were continuously monitored throughout the experiments and blood 
pressure was monitored every 15 minutes. 
 
The PET measurement was performed using a High Resolution Research Tomograph 
(HRRT) (Siemens Molecular Imaging) PET scanner122. List-mode data were 
reconstructed using the ordinary Poisson-3D-ordered subset expectation maximization 
(OP-3D-OSEM) algorithm, with 10 iterations and 16 subsets including modeling of the 
point spread function (PSF). A transmission scan of 6 minutes using a single 137Cs 
source was performed immediately before the injection of the radioligand. List-mode 
data were acquired continuously for 120 minutes at the same time as the intravenous 
injection of the radioligand.  During reconstruction the list mode data was subdivided 
into the following series of frames: 9x20 sec, 3x60 sec, 5x180 sec, 17x360 sec. 
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Brain MRI was performed in a 1.5-T GE Signa system (General Electric, Milwaukee, 
WI, USA). A T1 weighted image was obtained for coregistration with PET and the 
delineation of anatomic brain regions. The T1 sequence was a 3D spoiled gradient 
recalled (SPGR) protocol with the following settings: repetition time (TR) 21 ms, flip 
angle 35˚; FOV 12.8; matrix 256x256x128; 128x1.0 mm slices; 2 NEX. The sequence 
was optimized for a trade-off between a minimum of scanning time and a maximum of 
spatial resolution and contrast between gray and white matter. 
 
Before delineation of regions of interests (ROIs), the orientation of the brain was 
spatially normalized by having the high-resolution T1-weighted magnetic resonance 
images reoriented according to the line defined by the anterior and posterior 
commissures being parallel to the horizontal plane and the inter-hemispheric plane 
being parallel to the sagittal plane. The T1-weigted MR images were then re-sliced to 
the resolution of the HRRT PET system, 1.219x1.219x1.219 mm. The standardized T1-
weighted MR images were used as an individual anatomical template for the monkey. 
 
Regions of interest (ROIs) (the whole brain, the striatum, thalamus, cortex and 
cerebellum) were delineated on the realigned MRI image with the reference to the co-
registered PET using PMOD 3.1 (Zurich, Switzerland). Measurement of the uptake 
were analyzed by using standardized uptake value (SUV), which is the regional tissue 
radioactivity concentration normalized for the injected dose and body weight of the 
monkey. 
 
%SUV  %	injected	activitybrain	tissue	(ccm) body	weight	(g) 
 
3.6 RADIOMETABOLITE ANALYSIS 
 
Radiometabolite analysis was done by following a modified method used for other 
radioligands41. A reverse phase gradient radio-HPLC method was used for 
determination of the percentages of radioactivity corresponding to unchanged 
radioligands and radiometabolites during the course of a PET measurement. Venous 
blood samples (2 mL) were obtained from the monkey at different time points such as 
4, 15, 30, 45, 60, and 75 minutes after the injection of the radioligands. Plasma samples 
(0.5 mL) obtained after the centrifugation of blood at 2000 g for 2 minutes was mixed 
with acetonitrile (0.7 mL). The supernatant acetonitrile-plasma mixture (1.1 mL) was 
injected to a HPLC and the precipitate obtained after centrifugation at 2000 g for 2 
minutes was counted in a NaI well-counter. The well-counter consists of a NaI crystal 
(Harshaw, diameter: 38 mm x 50 mm; diameter of the well: 16 mm; depth: 38 mm). 
The crystal was housed inside a led shield cylinder with a wall thickness of approx 5 
cm. Furthermore, the crystal was coupled to a high voltage supply, set to 900V 
(Canberra, model 3002), an energy discriminator (Canberra, model 818) and a timer 
and counter (GE&E Ortec, model 871). Radioactive peaks eluting from the column 
were integrated and their areas expressed as a percentage of the sum of the areas of all 
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the detected radioactive peaks (decay-corrected). To calculate the recovery of 
radioactivity from the system, an aliquot (2 mL) of the eluate from the HPLC column 
was measured and divided with the amount of total injected radioanalyte. 
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4 RESULT AND DISCUSSIONS  
 
4.1 SYNTHESIS, RADIOLABELING AND BIOLOGICAL EVALUATION 
OF FLUORO ANALOGUES OF L-DEPRENYL FOR MAO-B (PAPER I 
AND PAPER II) 
  
Selegiline or L-deprenyl was the first compound discovered as a selective irreversible 
MAO-B inhibitor67. The action of L-deprenyl in the human brain is two-fold. Firstly, it 
preserves dopamine by selective inhibition of MAO-B and secondly, it inhibits the re-
uptake of dopamine and increases the synthesis rate of dopamine123-125. L-Deprenyl 
itself has been labeled with carbon-11 and was demonstrated as useful tracer for 
assessing MAO-B80, 81, 126. In this study we labeled L-deprenyl analogues with fluorine-
18 at different positions and evaluated their biological activity as PET radioligands for 
imaging brain MAO-B.     
 
4.1.1 Chemistry and radiochemistry 
 
Three novel fluorinated analogues of L-deprenyl N-(2-fluoroethyl)-N-(1-phenylpropan-
2-yl)prop-2-yn-1-amine (2), N-((1R,2S)-1-fluoro-1-phenylpropan-2-yl)-N-methylprop-
2-yn-1-amine (8) and (S)-N-(1-fluoro-3-phenylpropan-2-yl)-N-methyl prop-2-yn-1-
amine (13) were synthesized by multistep organic synthesis according to scheme 2. 
Three appropriate chloro-precursors N-(2-chloroethyl)-N-(1-phenylpropan-2-yl)prop-2-
yn-1-amine (4), N-((1R,2S)-1-chloro-1-phenylpropan-2-yl)-N-methylprop-2-yn-1-
amine (9) and a isomeric mixture of (S)-N-(1-chloro-3-phenylpropan-2-yl)-N-
methylprop-2-yn-1-amine (14) and N-(2-chloro-3-phenylpropyl)-N-methylprop-2-yn-1-
amine (15) for labeling with fluorine-18 were also synthesized. The formation of the 
isomeric mixtures of chlorides 14 and 15 can be explained by an intermediate 
aziridinium ion 17 resulting from an intramolecular nucleophilic attack (SNi) of the free 
electron pair of nitrogen127 according to scheme 3. Chlorides 14 and 15 were then 
formed by the subsequent nucleophilic attack (SN2) of Cl- at the corresponding reactive 
position of aziridinium ion 17. All compounds were identified by HPLC, NMR and 
LC-MS.  
 
The radiolabeling of all three compounds N-[2-[18F]fluoroethyl]-N-[(2R)-1-
phenylpropan-2-yl]prop-2-yn-1-amine (4a), N-[(1S,2R)-1-[18F]fluoro-1-phenyl propan-
2-yl]-N-methylprop-2-yn-1-amine (4b) and N-[(2S)-1-[18F]fluoro-3-phenyl propan-2-
yl]-N-methylprop-2-yn-1-amine ([18F]fluorodeprenyl, 4c) was achieved by a one-step 
nucleophilic substitution reaction according to scheme 2. Compound 4c was purified 
from the isomeric mixture by reversed phase HPLC. The overall radiosynthesis 
including radiofluorination, HPLC purification, and evaporation of the solvent and 
radiotracer formulation was completed in a time range of 70-80 minutes. The 
incorporation yield of the fluorination reactions varied from 40% to 70%, the 
radiochemical purity was greater than 99% and SA varied from 200 to 270 GBq/µmol 
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for all three radioligands. The identities of the labeled compounds were confirmed by 
co-injection of their corresponding fluorine-19 analogues 2, 8 and 13 using analytical 
HPLC. All three radioligands were found to be stable in PBS buffered solution 
(pH=7.4) for the duration of 120 min. 
 
 
 
Scheme 2: Synthesis of precursors, reference standards and radiolabeling. 
Conditions: a: NaOH/1-fluoro 2-bromo ethane;b: NaOH/1-bromo ethanol; c: TEA/mesyl chloride; d: 
LAH; e: K2CO3/propargyl bromide; f: DAST; g: TEA/mesyl chloride; h: LAH; i: K2CO3/propargyl 
bromide; j: DAST; k: TEA mesyl chloride; l,m,n: K18F, K-2,2,2/DMSO. 
 
 
 
Scheme 3: Proposed mechanism for the formation of 14 and 15. 
 
 
4.1.2 In vitro inhibition and autoradiography 
 
Compounds 2 and 8 inhibited MAO-B with an IC50 greater than 2 µM and were 
therefore, not further investigated. Compound 13 featured an IC50 of 31 ± 2.2nM for its 
MAO-B inhibitory activity while it was not inhibiting MAO-A (IC50>50 µM). L-
Deprenyl was used as a reference compound. It inhibited MAO-B with an IC50 of 
13±0.4 nM.  Thus, compound 13 inhibited MAO-B in a range comparable to that of the 
therapeutically used compound.  
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
21 
 
Compound 4c was demonstrated as a selective radioligand for the MAO-B enzyme by 
human brain ARG (Figure 3). At baseline condition (panel A) it shows binding to brain 
regions known to have a high content of MAO-B. For blocking, the MAO-B ligands L-
deprenyl (panel B), rasagiline (panel C) and the MAO-A ligand pirlindole (panel D) 
were used. Using the MAO-B ligands rasagiline and L-deprenyl the binding of 4c was 
completely blocked, whereas the MAO-A ligand pirlindole did not significantly block 
the total binding. This indicates that 4c is a selective radioligand of the MAO-B 
enzyme. 
 
 
Figure 3. Coronal slices of human brain autoradiograms labeled with 4c. (A) Baseline conditions.  (B) 
Incubation with L-deprenyl (10 µM), (C) Incubation with rasagiline (10 µM), (D) Incubation with 
pirlindole (10 µM). 
 
4.1.3 Biodistribution in mice and PET in non-human primate 
 
The biodistribution of compound 4c in mice showed a high initial brain uptake of 
radioactivity levelling at 5.2 ± 0.04 %ID/g at two minutes post injection (p.i.). The 
initial elimination of radioactivity from the brain was observed reaching a level of 1.9 ± 
0.33 % ID/g at 30 minutes (Figure 4). The biodistribution of compound 4c decreases as 
a function of time which differs to the literature data for [11C]deprenyl brain kinetics in 
mice80 where it increases as a function of time. It could be explained by that 4c is a 
chemically different compound as compared to deprenyl itself and/or the differences of 
the mouse strain, used in the experiment. 
   
 
 
 
Figure 4: Time course distribution of compound 4c in brain and blood of male NMRI mice. 
 
In comparative PET measurements, 4c in a cynomolgus monkey indicated irreversible 
binding kinetics similar to the binding characteristics obtained by [11C]deprenyl81 and 
the uptake of [18F]fluorodeprenyl at baseline condition was highest in the striatum 
followed by the thalamus, the cortex and the cerebellum (Figure 5 and 6).  
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Pre-administration of L-deprenyl (5 mg/kg) to the monkey resulted in about a six to 
eight fold decrease of radioactive uptake of 4c in the investigated brain regions (Figure 
7 and 8). This effect was similar to that reported for [11C]deprenyl in the baboon 
brain128. 
   
 
 
 
 
 
 
 
 
4.1.4 Radiometabolites measured in plasma 
 
Compound 4c showed relatively slower metabolism measured in monkey plasma 
compared to [11C]deprenyl. At 15 minutes p.i., approximately 38% of the plasma 
radioactivity was unchanged [11C]deprenyl, decreasing to 16% at 45 minutes p.i. 
whereas at 15 minutes after injection of 4c approximately 58% of the plasma 
radioactivity was unchanged parent radioligand, decreasing to 32% at 45 and 22% at 
120 minutes p.i. (Figure 9). 
 
 
 
Scheme 4: Proposed metabolism of L-deprenyl129. 
Figure 5. PET images of [11C]deprenyl and 
[18F]fluorodeprenyl (4c) co-registered with 
MRI averaged between 9 and 120 min in the 
horizontal (left), sagittal (middle) and coronal 
(right) projections (left)  
Figure 6. Brain uptake expressed as percent 
standardised uptake value (%SUV) in different 
brain regions after i.v. injection of 
[11C]deprenyl (left) and [18F]fluorodeprenyl 
(4c) (right) 
 
Figure 7. PET images of 4c co-registered 
with MRI averaged between 9 and 120 
minutes in the horizontal (left), sagittal 
(middle) and coronal (right) projections 
after pretreatment with L-deprenyl (5 
mg/kg) 
Figure 8. Brain uptake expressed as percent 
standardised uptake value (%SUV) after 
pretreatment with L-deprenyl (5 mg/kg). Time 
activity curves after i.v. injection of 4c in whole 
brain (left) and in different brain regions (right)  
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Radiometabolites of [11C]deprenyl have been extensively studied previously and found 
mainly to correspond to [11C]formic acid and its adducts, as well as 
[11C]methamphetamine129-132. It is also reported that three major urinary metabolites of 
L-deprenyl hydrochloride (N-methyl-N-propargyl(2-phenyl-1-methyl)ethylammonium 
chloride), were identified after administration to humans (Scheme 4).  Compound 4c 
showed a similar pattern of metabolism measured in monkey plasma reported for 
[11C]deprenyl. Therefore, there is a possibility of radiometabolites crossing the BBB 
and may complicate the quantification of PET data. 
 
 
Figure 9. Radiometabolite analysis during the time course of the PET measurements, [11C]deprenyl (left) 
and [18F]fluorodeprenyl (4c) (right). 
  
4.2 SYNTHESIS, RADIOLABELING AND BIOLOGICAL EVALUATION 
OF [18F]FLUORORASAGILINE FOR MAO-B (PAPER III) 
  
Rasagiline is a selective and irreversible MAO-B inhibitor which is co-administrated 
for the treatment of relieving symptoms resulting from the loss of dopaminergic 
neurons in Parkinson’s disease133. The two main metabolites of rasagiline are 
aminoindane and hydroxyaminoindan (Scheme 5) which in contrast to the 
amphetamine-like metabolites of L-deprenyl does not increase noradrenaline potency 
nor does it display any MAO-B inhibitory activity134, 135. Therefore, we used 
fluorinated rasagiline as the chemical entity for the development of a novel MAO-B 
PET ligand. 
 
 
 
Scheme 5: Proposed metabolism of R-rasagiline135. 
 
4.2.1 Chemistry and radiochemistry 
  
The precursor (3aS,8aR)-3-[prop-2-yn-1-yl]-3,3a,8,8a-tetrahydroindeno- [1,2-d][1,2,3] 
oxathiazole 2,2-dioxide (20) was synthesized from the starting material aminoindanol 
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(18) by multistep organic synthesis following a previously reported method136 (Scheme 
6). In the first step, 18 was treated with highly reactive sulfuryl chloride and the key 
parameter of this reaction was to keep the temperature at -65°C. In the second step, 
tetrahydroindeno[1,2-d][1,2,3]oxathiazole 2,2-dioxide (19) was alkylated with 
propargyl bromide to give the precursor compound (3) in a moderate 68% isolated 
yield, following a previously reported method136.   
 
 
Scheme 6. Synthesis of precursor (20) and reference standard (21) and [18F]fluororasagiline (23).  
Conditions: a: SO2Cl2/triethylamine; b: K2CO3/ propargyl bromide; c: CsF/5N HCl; d: K18F, K-
2,2,2/DMSO e: 0.5N HCl.  
 
The reference standard (1S,2S)-2-fluoro-N-(prop-2-yn-1-yl)-indan-1-amine 
(fluororasagiline, 21) was synthesized by two step synthesis from 20. The first step was 
substitution reaction with cesium fluoride followed by the hydrolysis of the 
sulphamidate group (Scheme 6). All compounds were identified by HPLC, NMR and 
LC-MS. 
 
The radiolabeling of (1S,2S)-2-[18F]fluoro-N-(prop-2-yn-1-yl)-indan-1-amine 
([18F]fluororasagiline, 23) was achieved by nucleophilic substitution of the 
sulphamidate precursors (20) by [18F]fluoride followed by deprotection of the 
sulphamidate group (Scheme 6). Different acids such as sulfuric acid, trifluoroacetic 
acid, hydroiodic acid and hydrochloric acid were tested for the hydrolysis of the 
sulphamidate group and 200 µL of 0.5N hydrochloric acid gave the highest yield. The 
radiochemical yield of the radiosynthesis was 50-55%, the radiochemical purity was 
higher than 99% and SA varied from 240 to 265 GBq/µmol for the radioligand. The 
identity of the labeled compound was confirmed by the co-injection of its 
corresponding fluorine-19 analogue 21 using analytical HPLC. Compound 23 was 
found to be stable in PBS buffered solution (pH=7.4) for the duration of 120 minutes. 
 
 
4.2.2 In vitro inhibition and autoradiography 
 
Inhibition of the enzymatic activities of MAO-B and MAO-A by fluorine-19 analogue 
of rasagiline (21) was determined based on the rate of 4-OH-quinoline generation from 
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kynuramine. The compound inhibited MAO-B with an IC50 = 27.0 ± 2.0 nM compared 
to rasgiline itself IC50 = 46.0 ± 2.2 nM. It is inhibiting MAO-A with an IC50 = 2.3 ± 
0.08 µM. Compound 21 was ca. 84 times more potent in inhibiting MAO-B versus 
MAO-A hinting at its specificity. 
 
Human whole hemisphere ARG was performed with 23. The signal intensities were 
highest in the hippocampus, the putamen, the caudate nucleus, the external globus 
pallidus and the thalamus. For blocking, the MAO-A ligand pirlindole and the MAO-B 
ligands L-deprenyl and rasagiline have been used in 10 µM concentrations (Figure 10). 
The MAO-B ligands rasagiline and L-deprenyl completely blocked the binding of 23, 
whereas the MAO-A ligand pirlindole did not block the binding. These observations 
indicate that 23 is a selective radioligand of MAO-B, whereas it displays negligible 
binding to the MAO-A isoform.   
   
 
Figure 10. Coronal slices of human brain autoradiograms labeled with 23 at baseline condition and 
incubation with pirlindole (10 µM), L-deprenyl (10 µM) and rasagiline (10 µM).  
 
4.2.3 PET in non-human primate 
 
Following the injection of 23 in a cynomolgus monkey, a reasonable amount (250 % 
SUV at 4 minutes p.i.) of radioactivity entered the brain (Figure 11 and 12). Due to the 
irreversible binding kinetics, [18F]fluororasagiline did not show any wash-out from the 
brain and the uptake of radioactivity at baseline condition was highest in the striatum 
and thalamus and lowest in the cerebellum and in cortical areas.  
 
   
 
 
 
 
4.2.4 Radiometabolites measured in plasma 
 
The metabolism of 23 was moderate and at 30 minutes approximately 60% of the 
plasma radioactivity represented the parent compound (Figure 13 (right)). HPLC 
Figure 11. PET images of 23 co-registered 
with MRI and averaged between 9 and 120 
minutes in the horizontal (left), coronal 
(middle) and sagittal (right) projections.   
 
Figure 12. Brain uptake expressed as percent 
standardised uptake value (%SUV) after i.v. 
injection of 23, in whole brain (left) and time 
activity curves in different brain regions (right). 
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analysis of the plasma following the injection of 23, which eluted at 7.7 minutes, 
revealed the presence of three more major peaks, [18F]a, [18F]fluoroaminoindan and 
[18F]b with retention times of 2.7, 4.6 and 9.2 minutes, respectively (Figure 13 (left)). 
 
Despite the promising brain uptake, the experiment revealed one potential problem 
with 23, namely that the radioactivity continued to increase slowly throughout the PET 
measurement. This finding may be explained by the brain penetration of 
radiometabolites. 
 
 
Figure 13 . Radiometabolite analysis at 30 minutes p.i. of [18F]fluororasagiline ( 23) (left) and during the 
time course of the PET measurements (right). 
 
 
4.3 SYNTHESIS, RADIOLABELING AND BIOLOGICAL EVALUATION 
OF ONE HETEROAROMATIC AND TWO ALIPHATIC PROPARGYL 
AMINES FOR MAO-B (PAPER IV) 
 
MAO-B can be irreversibly inactivated by propargylamine derivatives, where the 
oxidized propargylamine derivative binds to the flavin group of corresponding highly 
electrophilic eyniminium species by a covalent bond forming an adduct leading to  
inactivation of the enzyme by micromolar concentrations60. In this  study we designed 
one heteroaromatic propargylamine derivative ((S)-N-(1-fluoro-3-(furan-2-yl)propan-2-
yl)-N-methylprop-2-yn-1-amine (33)) and two aliphatic propargylamine derivatives 
((S)-1-fluoro-N,4-dimethyl-N-(prop-2-ynyl)pent-4-en-2-amine (28) and (S)-1-fluoro-
N,4-dimethyl-N-(prop-2-ynyl)pentan-2-amine (38)). Our aims were to prepare the 
precursors and reference standards and to develop efficient synthetic methods for 
labeling these radioligands with fluorine-18 and to evaluate their biological properties 
as PET radioligands for imaging MAO-B in the brain. 
 
4.3.1 Chemistry and radiochemistry 
  
Three novel fluorinated derivatives of propargyl amine 28, 33 and 38 (Scheme 7) were 
synthesized. In order to obtain respective radioligands three appropriate chloro-
precursors were also synthezised by multi-step organic synthesis. Amines 25, 30 and 35 
were prepared from the commercially available amino acid  (S)-2-(tert-
butoxycarbonylamino)-4-methylpent-4-enoic acid (24), (S)-tert-butyl 1-(furan-2-yl)-3-
hydroxypropan-2-ylcarbamate (29) and the amino acid (S)-4-methyl-2-(methylamino)- 
pentanoic acid (34) by reduction with LiAlH4 following a previously described 
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procedure.137  Amino alcohols 24, 29 and 34 were alkylated with propargyl bromide136 
and the obtained respective alcohols 26, 31 and 33 were chlorinated by treatment with 
mesyl chloride to synthesize the chloro precursors respectively. The formation of a 
mixture of two chlorinated isomers can be explained by a corresponding intermediate 
aziridinium ion resulting from an intramolecular nucleophilic attack (SNi) of the free 
electron pair of the nitrogen.127  Reference standards 28 and 33 were synthesized from 
amino alcohols 26 and 31 by fluorination reaction with diethylamino sulfurtrifluoride 
(DAST) and reference standard 38 was synthesized from amino alcohol 36 by treating 
with triethylamine trihydrofluoride. All compounds were identified by HPLC, NMR 
and LC-MS. 
 
 
Scheme 7. Synthesis of precursors and reference standards and radiolabeling of 39 and 40. 
Conditions: a: LAH; b: K2CO3/ propargyl bromide; c: DAST; d: pyridine/ mesyl chloride; e: LAH; f: 
K2CO3/ propargyl bromide; g:DAST; h: TEA/ mesyl chloride; i: LAH; j: K2CO3/ propargyl bromide; k: 
TEA/ DAST; l: TEA/ mesyl chloride; m: K18F, K-2,2,2/DMSO/ K2CO3. 
 
The radiolabeling of (S)-N-(1-[18F]fluoro-3-(furan-2-yl)propan-2-yl)-N-methylprop-2-
yn-1-amine (39) and (S)-1-[18F]fluoro-N,4-dimethyl-N-(prop-2-ynyl)pentan-2-amine 
(40)  was achieved by one step nucleophilic substitution reactions of the corresponding 
chloride precursors by [18F]fluoride in presence of K2.2.2 and K2CO3 as shown in 
scheme 7. Compounds 39 and 40 were purified from the corresponding reaction 
mixtures by semi preparative HPLC. The overall radiosynthesis including fluorination, 
HPLC purification, and evaporation of the solvent and radiotracer formulation was 
completed in a time range of 70-80 minutes. The incorporation yield of the fluorination 
reactions from fluorine-18 ion varied from 40% to 60%, and the radiochemical purity 
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was greater than 99% for both radiosynthesis. The specific radioactivity for 40 was 
between 192 and 240 GBq/µmol. The identities of the labeled compounds were 
confirmed by co-injection of their corresponding fluorine-19 analogues 33 and 38 using 
analytical HPLC. Both radioligands were found to be stable in PBS buffered solution 
(pH=7.4) for the duration of 150 minutes. 
 
4.3.2 In vitro inhibition and autoradiography 
  
IC50 values for inhibition were determined for compounds 28, 33 and 38 in order to 
determine their specificity for binding to MAO-B. Compound 28 inhibited MAO-B 
with an IC50 of 664 ± 48.08 nM and was discarded without further investigation. 
Whereas compounds 33 and 38 inhibited MAO-B in a range comparable to that of the 
therapeutically used compound deprenyl with IC50 values of 208.5 ± 13.44 nM and 
131.5 ± 0.71 nM. Therefore 33 and 38 were chosen for labeling with fluorine-18 for 
further investigation by ARG.  
 
The ARG signal intensities for both 39 and 40 were highest in the hippocampus, the 
putamen, the caudate nucleus and the thalamus. In order to test the specificity of the 
compound the binding was blocked with an excess (10 µM) of the MAO-B ligands L-
deprenyl and rasagiline and of the MAO-A ligand pirlindole, respectively (Figure 14). 
The MAO-B ligands rasagiline and L-deprenyl completely blocked the total binding of 
both 39 and 40. The MAO-A ligand pirlindole did not block the total binding 40 
whereas it could partly block the total binding of 39. These observations indicated that 
compound 40 is a selective radioligand of the MAO-B enzyme. Consequently, 40 was 
chosen for further examination using PET measurements of its brain uptake and 
distribution in a cynomolgus monkey. 
 
 
 
Figure 14. Coronal slices of human brain autoradiograms labeled with 40 at baseline condition and 
incubation with pirlindole (10 µM), L-deprenyl (10 µM) and rasagiline (10 µM). 
 
4.3.3 PET in non-human primate 
 
At baseline condition compound 40 readily crossed the BBB and bound rapidly to its 
target sites with a high brain uptake (250% SUV at 4 minutes) (Figure 15 and 16) but it 
was considerably lower than [18F]fluorodeprenyl (4c) (600-900% SUV at 4 minutes). 
Due to the irreversible binding kinetics, compound 40 did not show any wash-out from 
the brain. The uptake was highest in the striatum and the thalamus and lower in the 
cerebellum and the cortical areas, consistent with the known distribution of MAO-B 
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activity as previously reported for [11C]deprenyl81, and similar to what we found 
ourselves for 4c and 23 in this work.  
 
     
 
 
 
 
 
4.3.4 Radiometabolites measured in plasma 
 
The metabolic stability of 40 was lower compared to [18F]fluorodeprenyl and 
[18F]fluororasagiline and at 45 minutes only approximately 20% of the plasma 
radioactivity represented the parent compound and it decreased to 12% at 120 minutes 
(Figure 15). HPLC analysis of plasma following the injection of 40, which eluted at 7.3 
minutes, revealed the presence of five more major peaks with retention times of 2.0, 
3.4, 3.7, 4.2 and 6.2 minutes, respectively (Figure 17). 
 
 
Figure 17 . Radiometabolite analysis at 15 minutes p.i. of 40 (left) and during the time course of the PET 
measurements (right). 
 
Despite the promising brain uptake and distribution, the experiment revealed one 
potential problem that the radioactivity continued increasing slowly throughout the PET 
measurement. This finding may be explained by the brain penetration of 
radiometabolite(s). 
 
4.4 SYNTHESIS, RADIOLABELING AND BIOLOGICAL EVALUATION 
OF [18F]FLUORODEPRENYL-D2 AND [18F]FLUORORASAGILINE-D2 
FOR MAO-B (PAPER V AND PAPER VI) 
 
Kinetic isotope effect has widely been used in the elucidation of organic as well as in 
enzymatic reaction mechanism138. The deuterium isotope effect plays an important role 
Figure 16. Brain uptake expressed as percent 
standardised uptake value (%SUV) after i.v. injection 
of 40, in whole brain (left) and time activity curves 
in different brain regions (right). 
Figure 15. PET images of 40 co-
registered with MRI and averaged 
between 9 and 120 minutes in the 
horizontal (left), coronal (middle) and 
sagittal (right) projections.   
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in the oxidative deamination of amines by MAO139. Thus the MAO-B catalyzed bond 
cleavage of a carbon-hydrogen bond of propargyl group at the α carbon is the rate 
limiting step in the retention of radioligand in the brain140. Therefore, in the rate-
limiting step of the enzymatic catalysis, MAO-B cleaves a C–D bond in the methylene 
group of the propargyl group and generates a reactive intermediate that irreversibly 
binds to the enzyme141. The energy required to cleave the C-D bond is higher than that 
required to cleave the C-H bond and the substitution of hydrogen atoms with deuterium 
atoms, reduces the rate of cleavage142.  
 
Applying this principle earlier, the deuterium substituted analogue of [11C]deprenyl 
([11C]deprenyl-D2)  was developed to image MAO-B in brain demonstrating lower 
uptake and better sensitivity compared to [11C]deprenyl83, 84, 143, 144. This study is the 
continuation of our previous study (paper II and paper III) where we reported in vivo 
evaluation of MAO-B in cynomolgus monkey brain using 4c and 23. In order to reduce 
the rate of radioligand trapping in human brain and thus, to improve its sensitivity as 
well as in order to reduce the amount of radiometabolites in blood plasma which 
potentially can penetrate the BBB and thereby may complicate reliable quantification, 
both 4c and 23 were deuterated.   
 
4.4.1 Chemistry and radiochemistry 
  
Precursors (46 and 48) and reference standards (45 and 49) were synthesized in multi-
step organic syntheses from the starting material propiolic acid (Scheme 8). The 
intermidate (1,1-2H2)prop-2-yn-1-ol (42) was synthesized by treating propiolic acid 
with lithium aluminum deuteride. The key parameter of this reaction was to keep the 
temperature at below 50°C and purification of the compound because of its low boiling 
point. In the second step, 42 was brominated with PBr3 to synthesise the compound 
(1,1-2H2)3-bromoprop-1-yne (43). Compound 44 was synthesized from 43 and the 
previously synthesized compound (4R,5R)-4-methyl 5-phenyl-3-(prop-2-ynyl) 
oxazolidin-2-one following a previously described procedure136. The formation of 
regioisomeric chlorides 46a and 46b can be explained by an intermediate aziridinium 
ion  resulting from an intramolecular nucleophilic substitution attack (SNi) of the free 
electron pair of the nitrogen which has been previously described elsewhere 127. 
Compound 48 was synthesized from 43 and the the previously synthesized compound 
tetrahydroindeno[1,2-d][1,2,3]oxathiazole 2,2-dioxide following a previously reported 
method. Reference standard (1S,2S)-2-fluoro-N-[(1,1-2H2)prop-2-yn-1-yl]indan-1-
amine (49) was synthesized with an inversion of configuration from 48 by a two-step 
synthesis. The first step was a substitution reaction with cesium fluoride where the 
cyclic sulphamidate group was opened by a fluoride ion followed by the hydrolysis of 
the sulphamidate group by addition of 4N hydrochloric acid and ethanol. All 
compounds were identified by NMR, HPLC and LC-MS. 
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Scheme 8. Synthesis of precursors and reference standards and radiolabeling of [18F]fluorodeprenyl-D2 
(47) and [18F]fluororasagiline-D2 (50).  
Conditions: a: LAD; b: PBr3; c: K2CO3/ S)-2-(methyl(prop-2-ynyl)amino)-3-phenylpropan-1-ol; d: 
pyridine/mesyl chloride; e: DAST; f: K18F, K-2,2,2/DMSO/ K2CO3; g: (3aS,8aR)-3,3a,8,8a-tetrahydro 
indeno[1,2-d][1,2,3]oxathiazole 2,2-dioxide/ K2CO3; h: CsF/5N HCl; i: K18F, K-2,2,2/DMSO/ K2CO3 
 
Radiolabeling of both compounds was accomplished by a nucleophilic substitution 
reaction via SN2 mechanism and the deprotection of sulphamidate group in the case of 
50, hydrolysis was performed with 150 µL of 1.0 N hydrochloric acid.  The 
incorporation radiochemical yield from fluorine-18 ion was 35-50%.  The 
radiochemical purity was higher than 99% and the specific radioactivity was in a range 
of 200 to 235 GBq/µmol at the time of administration for both 47 and 50. Both 
radioligands were found to be stable at three hours after formulation in a sterile 
phosphate buffered solution (pH = 7,4).  
  
4.4.2 In vitro inhibition 
  
In vitro MAO inhibition was determined for both 19F-fluorodeprenyl-D2 and 19F-
fluororasagiline-D2 in an enzymatic assay with kynuramine as substrate. 19F-
Fluorodeprenyl-D2 inhibited the MAO-B activity with an IC50 of 227 ± 36.8 nM and 
the MAO-A activity with an IC50 of >50 µM.  Thus, deuteration decreased the IC50 
towards MAO-B by ca. 7 times as compared to the non-deuterated fluorodeprenyl in 
the assay used. 19F-Fluororasagiline-D2 inhibited MAO-B with an IC50 = 173.0 ± 13.6 
nM while inhibited MAO-A with an IC50 = 9.9 ± 1.1 µM.  
 
 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
32 
 
4.4.3 PET in non-human primate  
  
PET images and the time activity curves (TAC) of 47 and 50 uptake in a cynomolgus 
monkeys brain is shown in Figure 18-21. Both compounds cross the blood-brain barrier 
and bind rapidly. The brain uptake in a baseline condition was ~250% SUV and thus, in 
a similar range of other typical useful radioligands. The uptake was highest in the 
striatum and the thalamus followed by in the cortical areas and the cerebellum. This is 
consistent with the known distribution of in vivo MAO-B activity as previously 
reported for [11C]deprenyl81. Both 47 and 50
 
showed faster wash-out from the brain and 
less accumulation in cortical and sub-cortical regions than compared to their non-
deuterated analogues.  
 
   
 
 
 
 
Deuteration of 4c lead to a significantly decreased uptake in the investigated brain 
regions. The effect of deuteration on the decrease in signal intensity for the 
[11C]deprenyl–D2 observed in healthy baboon and human brain regions was 
approximately 1.2 – 2.091. In this study, we demonstrated a decrease in signal intensity 
of 5-6 times as a consequence of [18F]fluorodeprenyl deuteration.   
 
In the case of 50, the signal intensity in target regions was up to 3 times lower than that 
in the case of [18F]rasagiline (Figure 21). The reduced trapping rate of 50 enables an 
improved quantification of MAO-B activity and avoids blood flow limitation of 
delivery of the tracer, since it is known that a high trapping rate is responsible for an 
underestimation of the MAO-B signal in regions with high MAO-B activity.  
 
  
 
 
 
 
 
Figure 18. PET images of 47 baseline condition 
co-registered with MRI and averaged between 9 
and 120 minutes in the horizontal (left), coronal 
(middle) and sagittal (right) projections. 
 
Figure 19. Brain uptake expressed as percent 
standardised uptake value (%SUV) after i.v. 
injection of 47, in whole brain (left) and time 
activity curves in different brain regions (right). 
 
Figure 20. PET images of 50 baseline 
condition co-registered with MRI and averaged 
between 9 and 120 minutes in the horizontal 
(left), coronal (middle) and sagittal (right) 
projections. 
Figure 21. Brain uptake expressed as percent 
standardised uptake value (%SUV) after i.v. 
injection of 50, in whole brain (left) and time 
activity curves in different brain regions (right). 
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The administration of 5 mg/kg of the MAO-B inhibitor L-deprenyl 30 minutes prior to 
the injection of 50 resulted in an approximately 50% decrease in the accumulation of 
the radioligand at 120 minutes p.i. in all brain regions (Figure 22 and 23). 
 
     
 
 
 
  
 
4.4.4 Radiometabolites measured in plasma 
  
Radiometabolites of the radioligands measured in monkey plasma were analyzed by 
HPLC. Both radioligands
 
showed a slower radiometabolism when compared to their 
non-deuterated analogues.  Compound 47 showed similar pattern of metabolism as 
reported for both [11C]deprenyl128, 145 and [11C]deprenyl-D291.The two radiometabolites 
of [11C]deprenyl have been extensively studied previously and have been found to 
correspond to [11C]formic acid and its adducts, and [11C]methamphetamine130, 146. 
Therefore the present compound will also more likely to have a radiometabolite which 
correspons to [18F]fluoromethamphetamine.  
 
 
Figure 24. Radiometabolite analysis at 45 minutes p.i. of 47 (left) and during the time course of the 
PET measurements (right). 
 
Compound 47 produced four radiometabolites with lower lipophilicity than the parent 
compound as judged from its short retention time on HPLC (Figure 24 left). At 15 
minutes p.i. approximately 60% of the plasma radioactivity was unchanged 47, 
decreasing to 45% at 45 minutes p.i. and 35% at 120 minutes p.i. (Figure 24 right).  
 
For 50, approximately 75% of the plasma radioactivity was unchanged parent 
compound at 15 minutes p.i., decreasing to 55% at 45 minutes p.i. and 35% at 120 
minutes p.i. (Figure 25 right). Two radiometabolites, a and b (Figure 25 left) with 
lower lipophilicity than the parent compound were found. Radiometabolite a was more 
Figure 22. PET images of 50 co-registered with 
MRI and averaged between 9 and 120 minutes in 
the horizontal (left), coronal (middle) and sagittal 
(right) projections after pretreatment with L-
deprenyl (5 mg/kg). 
 
Figure 23. Brain uptake expressed as percent 
standardised uptake value (%SUV) after 
pretreatment with L-deprenyl (5 mg/kg). Time 
activity curves after i.v. injection of 50 in whole 
brain (left) and in different brain regions (right)  
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abundant, representing approximately 35% of the plasma radioactivity at 120 minutes 
p.i. whereas b was less abundant with approximately 20% of the total plasma 
radioactivity at 120 minutes. As a consequence of deuteration we demonstrated that the 
metabolic stability of the parent compound was significantly increased. In addition, in 
the previous study with 23, we observed a more lipophilic radiometabolite compared to 
the parent compound, which was eliminated after deuteration.  
    
 
Figure 25. Radiometabolite analysis at 45 minutes p.i. of 50 (left) and during the time course of the PET 
measurements (right). 
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5 SUMMARY OF FINDINGS 
  
Firstly, the two well established MAO-B inhibitors such as L-deprenyl and rasagiline 
were chosen to be labeled with fluorine-18. Fluorinated analogues of L-deprenyl were 
labeled with fluorine-18 at three different positions (4a, 4b and 4c). In vitro and in vivo 
studies demonstrated that only 4c ([18F]fluorodeprenyl) binds specifically to MAO-B 
rich regions of the brain and showed a similar kinetic behavior as previously reported 
for [11C]deprenyl. Therefore, quantification of MAO-B using 4c may be difficult 
because of fast irreversible binding to the enzyme renders the distribution of this 
radioligand in tissue limited by blood flow rather than the MAO-B enzyme 
concentration. On the other hand, with 23 ([18F]fluororasagiline) we observed  a 
continuing increase of the radioactivity in brain throughout the PET measurement that 
may indicate a blood-brain barrier penetrating radiometabolite that may in turn 
complicate a reliable quantification. 
 
Secondly, three different fluorinated analogues of propargyl amines (28, 33 and 38) 
were synthesized and tested for inhibition of MAO-B. Compounds 33 and 38 inhibited 
MAO-B in a range comparable to that of the therapeutically used compound deprenyl, 
and were chosen for fluorine-18 labeling for further investigation by ARG and PET. In 
vitro and in vivo studies demonstrated that only 38 binds specifically to MAO-B rich 
regions of the brain and showed similar kinetic behavior as previously reported for 23 
i.e.  a continuing increase of the radioactivity throughout the PET measurement. 
 
Finally, in order to reduce the rate of radioligand trapping in human brain and thus, to 
improve its sensitivity as well as to reduce the radiometabolism measured in plasma, 
we synthesized fluorine-18 labeled deuterated fluorodeprenyl 47 and deuterated 
fluororasagiline 50 and examined them as novel PET radioligands for MAO-B. In vitro 
inhibition showed that both 47 and 50 inhibited MAO-B selectively.  Both 47 and 50 
were examined in the cynomolgus monkey brain where a high brain uptake was found 
(~250% SUV at 4 minutes) with higher amounts in the striatum and the thalamus 
compared to the cortex and the cerebellum as well as a faster wash-out from the brain. 
A radiometabolite study demonstrated that both 47 and 50 were more stable measured 
in monkey plasma as a consequence of deuteration when compared to the non-
deuterated analogues. 
 
These results together suggest that 47
 
and 50
 
are improved PET radioligands for 
imaging MAO-B.  
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6 FUTURE PERSPECTIVES AND CHALLENGES 
 
Due to its central role in neurotransmitter metabolism, MAO-B represents an attractive 
drug target in the pharmacological therapy of neurodegenerative diseases. The MAO-B 
enzyme is upregulated in reactive astrocytes, giving rise to increased regional uptake of 
MAO-B inhibitors. Therefore, radiolabeled MAO-B inhibitors may be potential 
imaging biomarkers due to their affinity to the MAO-B enzyme for neurodegeneration. 
This thesis reported the development of two radiolabeled MAO-B inhibitors such as 47 
([18F]fluorodeprenyl-D2) and 50 ([18F]fluororasagiline-D2) effective for imaging MAO-
B by PET. 
 
Based on this work some future perspectives and specific challenges can be discussed 
for clinical use of 47
 
and 50
 
as PET radioligands. 
 
Radiochemistry and purification 
 
A PET radioligand, whether for clinical or preclinical use, should show a high level of 
chemical and radiochemical purity (typically >95%) also the radiosynthesis and 
purification should be performed as fast as possible. One step radiosynthesis is 
preferable for a PET radioligand to be clinically successful. Compound 47 was 
synthesized in one step simple nucleophilic substitution reaction. The final product is a 
mixture of two radiolabeled isomers which were purified by semi-preparative HPLC. It 
is quite complicated to purify the isomers by only solid phase extraction (SPE) alone, 
which is a common procedure for synthetic module that is not equipped with a HPLC 
for purification. Therefore, a future challenge will be to synthesize 47
 
as an 
isomerically pure compound. The synthesis of 50
 
was accomplished in two reaction 
steps. A future development will be to develop a one-step labeling procedure. 
 
Analysis of radiometabolites 
 
In a PET investigation, it is impossible to distinguish whether the radioactive uptake in 
the brain is dominated by signals from the parent radiotracer or its radiolabeled 
metabolites. After administration of both 47
 
and 50,
 
radiometabolite studies in monkey 
plasma, demonstrated the presence of several radiometabolites which were not 
extensively investigated and identified. Therefore, an additional future challenge would 
be a detailed analysis of BBB penetrating radiometabolites which can influence the 
quantification. 
 
Binding kinetics 
 
One potential disadvantage of using both 47
 
and 50
 
is the irreversible nature of their 
binding kinetics. As quantification of a reversible binding radioligand is generally 
preferable over an irreversible one, therefore, a final future prospective will be focused 
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on developing new PET radioligands for MAO-B with a reversible binding 
characteristic.  
 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
38 
 
7 ACKNOWLEDGEMENTS 
 
I would like to express my sincere gratitude and appreciation to all of them who have 
contributed directly or indirectly to make this thesis possible. I would specially like to 
thank: 
 
Professor Christer Halldin, my supervisor, for accepting me as a PhD student in your 
group, your guidance and encouragement, enthusiasm, being available no matter where 
in the world you were as well as your ultimate support throughout these years. You 
have prepared me to meet new challenges in my future scientific career. 
 
Dr. Lutz Lehmann, Dr. Georg Kettschau, Dr. Andrea Thiele and  Dr. Tobias Heinrich 
for welcoming me at the Medicinal Chemistry lab of Bayer HealthCare AG and for 
your scientific discussion, constructive criticism and valuable comments during this 
work. Astrid Knop, for your technical support in the lab. 
 
Associate Professor Andrea Varrone, for helping with PET data analysis and your 
positive comments as well as encouragement all the time. Professor Balazs Gulyas for 
helping with autoradiography and your valuable comments for writing manuscripts and 
Miklos Toth, for helping with PET data analysis.  
 
All present and previous colleagues at the radiochemistry group at the Karolinska 
Institutet: Dr Anu J Airaksinen, for introducing me into the radiochemistry, Dr Magnus 
Schou for friendship and excellent scientific discussions about chemistry and 
radiochemistry, Dr. Obaidur Rahman for friendship and valuable discussions about 
science and life,  Dr Jan Andersson for being a nice officemate for many years even 
though I was unable to teach you cricket, Kenneth Dahl and Phong Trong for your 
friendship and technical assistance. 
 
A special thanks to Gudrun Nylen and Siv Eriksson for your excellent assistance with 
the monkey PET study and ARG respectively. Karin Zahir, for a great administrative 
assistance.   
 
Arsalan Amir, Guennadi Jogolev, Dr. Jonas Bergström and Dr. Ryuji Nakao for 
excellent assistance  with quality control and metabolite analysis in this thesis work. I 
thank all other members of the radiochemistry group who have made life at work 
easygoing: Dr. Zhisheng Jia, Carsten Steiger, Dr. Peter Johnström, Anna Sumic, Linda 
Bergman, Dr. Raisa Krasikova, Henrik Alfredeen, Dr. Nahid Amini, Dr. Vladimir 
Stepanov, Jacob Kihlström, Hanna Jacobson, Andreas Westermark, Nandor Kaposy, 
Mirkka Sarparanta, Dr. Sean Donohue, Dr. Stefan Martinsson and Dr. Fabienne 
Gourand. 
 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
39 
 
All current and previous colleagues at the PET imaging group at the Karolinska 
Institutet: Dr. Sjoerd Finnema, Dr. Akihiro Takano, Dr. Anton Forsberg, Dr. Johan 
Lundberg, Dr. Katarina Varnäs, Dr. Per Kalsson, Dr. Jacqueline Borg, Dr. Simon 
Cervenka, Dr. Mikael Tiger, Dr. Magdalena Nord, Martin Schain, and Dr. Pavitra 
Kannan. 
 
Karin Zahir, Urban Hansson, Karin Olsson, Göran Rosenqvist, Nils Sjöholm, Marianne 
Youssefi, Anncathrin Kallin, Johan Molin, Pia Schönbeck, Sofia Sjödin, Nina Knave 
for being a nice bunch of people. 
 
Members of the radiochemistry group of the Karolinska pharmacy, Professor Sharon 
Stone-Elander, Dr. Jan-Olov Thorell, Erik Samen and Emma Jussing for smooth co-
operation in the radiochemistry labs. 
 
Professor Bengt Långström for giving the opportunity to do a project work in your 
group and Professor Stefan Sjöberg for introducing me to the Uppsala University and 
Professor Bengt Långström. 
 
Professor M Mosihuzzaman, Professor Nilufar Nahar and Associate Professor Iqbal 
Rouf Mamun for giving me the opportunity to work with you and always inspiring me 
for research. 
 
Friends: Emo, Kristofer, Dipu, Feku, Bernt, Shimul, Pamela, Kazi and Ratan bhai. 
Thanks for all support. Momin, thanks for friendship and all technical supports with 
computer. 
 
My amazing family: Bapi, ma, dada and Biku. Thanks for your endless love and 
support, without which I wouldn’t have come here today. 
 
Finally I especially thank Jolly (Mahabuba Jahan) and Leeba for making a nice and 
happy family in Sweden and for your eternal support, inspiration and love. Jolly I 
would also like to thank for your positive and constructive criticisms/suggestions about 
chemistry and writing the thesis. 
 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
40 
 
8 REFERENCES 
 
1. Phelps M. E. PET: a biological imaging technique. Neurochem Res 1991, 
16, 929-40. 
2. Welch M. J. and Redvanly C. S. Handbook of Radiopharmaceuticals: 
Radiochemistry and Application. John Wiley & Sons Ltd, West Sussex, England 2003. 
3. Ell P. J. and Gambhir S. S. Nuclear Medicine in Clinical Diagnosis and 
Treatment. Elsevier Ltd 2004, 1. 
4. Cassidy P. J. and Radda G. K. Molecular imaging perspectives. J R Soc 
Interface 2005, 2, 133-44. 
5. Eriksson L., Dahlbom M. and Widen L. Positron emission tomography--a 
new technique for studies of the central nervous system. J Microsc 1990, 157, 305-33. 
6. Cherry S. R. and Gambhir S. S. Use of positron emission tomography in 
animal research. ILAR J 2001, 42, 219-32. 
7. Basu S. and Alavi A. Unparalleled contribution of 18F-FDG PET to 
medicine over 3 decades. J Nucl Med 2008, 49, 17N-21N, 37N. 
8. Morrish P. K., Rakshi J. S., Bailey D. L., Sawle G. V. and Brooks D. J. 
Measuring the rate of progression and estimating the preclinical period of Parkinson's 
disease with [18F]dopa PET. J Neuro Neuro Psy 1998, 64, 314-9. 
9. Tolboom N., Yaqub M., van der Flier W. M., Boellaard R., Luurtsema 
G., Windhorst A. D., Barkhof F., Scheltens P., Lammertsma A. A. and van Berckel B. 
N. Detection of Alzheimer pathology in vivo using both [11C]-PIB and 18F-FDDNP 
PET. J Nucl Med 2009, 50, 191-7. 
10. Guadagno J. V., Warburton E. A., Jones P. S., Day D. J., Aigbirhio F. I., 
Fryer T. D., Harding S., Price C. J., Green H. A., Barret O., Gillard J. H. and Baron J. 
C. How affected is oxygen metabolism in DWI lesions?: A combined acute stroke 
PET-MR study. Neurology 2006, 67, 824-9. 
11. Gee A. D. Neuropharmacology and drug development. Br Med Bull 
2003, 65, 169-77. 
12. Halldin C., Gulyas B. and Farde L. PET studies with carbon-11 
radioligands in neuropsychopharmacological drug development. Curr Pharm Des 
2001, 7, 1907-29. 
13. Passchier J., Gee A., Willemsen A., Vaalburg W. and van Waarde A. 
Measuring drug-related receptor occupancy with positron emission tomography. 
Methods 2002, 27, 278-86. 
14. Gatley S. J., Volkow N. D., Fowler J. S., Ding Y. S., Logan J., Wang G. 
J. and Gifford A. N. Positron emission tomography and its use to image the occupancy 
of drug binding sites. Drug Development Research 2003, 59, 194-207. 
15. Farde L. and Hall H. Positron emission tomography--examination of 
chemical transmission in the living human brain. Development of radioligands. 
Arzneimittelforschung 1992, 42, 260-4. 
16. Lee C. M. and Farde L. Using positron emission tomography to facilitate 
CNS drug development. Trends Pharmacol Sci 2006, 27, 310-6. 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
41 
 
17. Bergstrom M., Grahnen A. and Langstrom B. Positron emission 
tomography microdosing: a new concept with application in tracer and early clinical 
drug development. Eur J Clin Pharmacol 2003, 59, 357-66. 
18. Molecular imaging that will bring about a revolution in diagnosis and 
drug discovery. Riken Research 
http://www.rikenresearch.riken.jp/eng/frontline/5656.html 2008. 
19. Halldin C., Gulyas B., Langer O. and Farde L. Brain radioligands--state 
of the art and new trends. Q J Nucl Med 2001, 45, 139-52. 
20. Pike V. W. PET radiotracers: crossing the blood-brain barrier and 
surviving metabolism. Trends Pharmacol Sci 2009, 30, 431-40. 
21. Laruelle M., Slifstein M. and Huang Y. Relationships between radiotracer 
properties and image quality in molecular imaging of the brain with positron emission 
tomography. Mol Imaging Biol 2003, 5, 363-75. 
22. Waterhouse R. N. Determination of lipophilicity and its use as a predictor 
of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003, 
5, 376-89. 
23. Pike V. W. Positron-emitting radioligands for studies in vivo-probes for 
human psychopharmacology. J Psychopharmacol 1993, 7, 139-58. 
24. Elsinga P. H. Radiopharmaceutical chemistry for positron emission 
tomography. Methods 2002, 27, 208-17. 
25. Wong D. F. and Pomper M. G. Predicting the success of a 
radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor 
systems. Mol Imaging Biol 2003, 5, 350-62. 
26. Dickson C. J., Gee A. D., Bennacef I., Gould I. R. and Rosso L. Further 
evaluation of quantum chemical methods for the prediction of non-specific binding of 
positron emission tomography tracers. Phys Chem Chem Phys 2011, 13, 21552-7. 
27. Dishino D. D., Welch M. J., Kilbourn M. R. and Raichle M. E. 
Relationship between lipophilicity and brain extraction of C-11-labeled 
radiopharmaceuticals. J Nucl Med 1983, 24, 1030-8. 
28. Moerlein S. M., Laufer P. and Stocklin G. Effect of lipophilicity on the in 
vivo localization of radiolabelled spiperone analogues. Int J Nucl Med Biol 1985, 12, 
353-6. 
29. Seddon A. M., Casey D., Law R. V., Gee A., Templer R. H. and Ces O. 
Drug interactions with lipid membranes. Chem Soc Rev 2009, 38, 2509-19. 
30. Patel S. and Gibson R. In vivo site-directed radiotracers: a mini-review. 
Nucl Med Biol 2008, 35, 805-15. 
31. Elsinga P. H., Hendrikse N. H., Bart J., Vaalburg W. and van Waarde A. 
PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake 
and binding of drugs within the CNS. Curr Pharm Des 2004, 10, 1493-503. 
32. Kannan P., John C., Zoghbi S. S., Halldin C., Gottesman M. M., Innis R. 
B. and Hall M. D. Imaging the function of P-glycoprotein with radiotracers: 
pharmacokinetics and in vivo applications. Clin Pharmacol Ther 2009, 86, 368-77. 
33. Raub T. J. P-glycoprotein recognition of substrates and circumvention 
through rational drug design. Mol Pharm 2006, 3, 3-25. 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
42 
 
34. Olsson H., Halldin C. and Farde L. Differentiation of extrastriatal 
dopamine D2 receptor density and affinity in the human brain using PET. Neuroimage 
2004, 22, 794-803. 
35. Bergman J., Eskola O., Lehikoinen P. and Solin O. Automated synthesis 
and purification of [18F]bromofluoromethane at high specific radioactivity. Appl Radiat 
Isot 2001, 54, 927-33. 
36. Lapi S. E. and Welch M. J. A historical perspective on the specific 
activity of radiopharmaceuticals: what have we learned in the 35 years of the ISRC? 
Nucl Med Biol 2012, 39, 601-8. 
37. Fortt R. and Gee A. Microfluidics: a golden opportunity for positron 
emission tomography? Future Med Chem 2013, 5, 241-4. 
38. Lu S. Y. and Pike V. W. Micro-reactors for PET tracer labeling. Ernst 
Schering Res Found Workshop 2007, 271-87. 
39. Langstrom B., Itsenko O. and Rahman O. C-11 Carbon monoxide, a 
versatile and useful precursor in labelling chemistry for PET ligand development. 
Journal of Labelled Compounds & Radiopharmaceuticals 2007, 50, 794-810. 
40. Dahl K., Schou M., Amini N. and Halldin C. Palladium-Mediated C-11 
Carbonylation at Atmospheric Pressure: A General Method Using Xantphos as 
Supporting Ligand. European Journal of Organic Chemistry 2013, 1228-1231. 
41. Halldin C., Swahn C. G., Farde L. and Sedvall G. Radioligand disposition 
and metabolism. Kluwer Academic Publishers 1995, 55. 
42. Chitneni S. K., Serdons K., Evens N., Fonge H., Celen S., Deroose C. M., 
Debyser Z., Mortelmans L., Verbruggen A. M. and Bormans G. M. Efficient 
purification and metabolite analysis of radiotracers using high-performance liquid 
chromatography and on-line solid-phase extraction. J Chromatography A 2008, 1189, 
323-331. 
43. Osman S., Lundkvist C., Pike V. W., Halldin C., McCarron J. A., Swahn 
C. G., Farde L., Ginovart N., Luthra S. K., Gunn R. N., Bench C. J., Sargent P. A. and 
Grasby P. M. Characterisation of the appearance of radioactive metabolites in monkey 
and human plasma from the 5-HT1A receptor radioligand, [11C]WAY-100635--
explanation of high signal contrast in PET and an aid to biomathematical modelling. 
Nucl Med Biol 1998, 25, 215-23. 
44. Hare M. L. Tyramine oxidase: A new enzyme system in liver. Biochem J 
1928, 22, 968-79. 
45. Blaschko H., Richter D. and Schlossmann H. The inactivation of 
adrenaline. J Physiol 1937, 90, 1-17. 
46. Zeller E. A. Über den enzymatischen Abbau von Histamin und 
Diaminen. 2. Mitteilung. Helvetica Chimica Acta 1938, 21, 880-890. 
47. Singer T. P. and Ramsay R. R. Flauoprotein structure and mechanism 2. 
Monoamine oxidases: old friends hold many surprises. FASEB J 1995, 9, 605-10. 
48. Bach A. W. J., Lan N. C., Bruke D. J., Abell C. W., Bembenek M. E., 
Kwan S. W., Seeburg P. H. and Shih J. C. Molecular-cloning of human monoamine 
oxidase-A and oxidase-B (MAO-A and MAO-B). Faseb Journal 1988, 2, A1733-
A1733. 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
43 
 
49. Tipton K. F., Boyce S., O'Sullivan J., Davey G. P. and Healy J. 
Monoamine oxidases: Certainties and uncertainties. Curr Med Chem 2004, 11, 1965-
1982. 
50. Smith M. A., Rottkamp C. A., Nunomura A., Raina A. K. and Perry G. 
Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 2000, 1502, 139-44. 
51. Su A. I., Wiltshire T., Batalov S., Lapp H., Ching K. A., Block D., Zhang 
J., Soden R., Hayakawa M., Kreiman G., Cooke M. P., Walker J. R. and Hogenesch J. 
B. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl 
Acad Sci U S A 2004, 101, 6062-7. 
52. Levitt P., Pintar J. E. and Breakefield X. O. Immunocytochemical 
demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. 
Proc Natl Acad Sci U S A 1982, 79, 6385-9. 
53. Shih J. C., Chen K. and Ridd M. J. Monoamine oxidase: from genes to 
behavior. Annu Rev Neurosci 1999, 22, 197-217. 
54. Nakamura S., Kawamata T., Akiguchi I., Kameyama M., Nakamura N. 
and Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile 
plaques. Acta Neuropathol 1990, 80, 419-25. 
55. Cesura A. M. and Pletscher A. The new generation of monoamine 
oxidase inhibitors. Prog Drug Res 1992, 38, 171-297. 
56. Oreland L., Arai Y., Stenstrom A. and Fowler C. J. Monoamine oxidase 
activity and localisation in the brain and the activity in relation to psychiatric disorders. 
Mod Probl Pharmacopsychiatry 1983, 19, 246-54. 
57. Squires R. F. Multiple forms of monoamine oxidase in intact 
mitochondria as characterized by selective inhibitors and thermal stability: a 
comparison of eight mammalian species. Adv Biochem Psychopharmacol 1972, 5, 355-
70. 
58. Yamada M. and Yasuhara H. Clinical pharmacology of MAO inhibitors: 
safety and future. Neurotoxicology 2004, 25, 215-21. 
59. Fariello R. G. and Lieberman A. Present and future approaches to 
Parkinson disease: from molecular insights to new therapeutic avenues. Neurology 
2006, 67, S1-4. 
60. Youdim M. B. H. and Bakhle Y. S. Monoamine oxidase: isoforms and 
inhibitors in Parkinson's disease and depressive illness. British J Pharm 2006, 147, 
S287-S296. 
61. Bortolato M., Chen K. and Shih J. C. Monoamine oxidase inactivation: 
from pathophysiology to therapeutics. Adv Drug Deliv Rev 2008, 60, 1527-33. 
62. Andrews J. M. and Nemeroff C. B. Contemporary management of 
depression. Am J Med 1994, 97, S24-S32. 
63. Drukarch B. and van Muiswinkel F. L. Drug treatment of Parkinson's 
disease - Time for phase II. Biochemical Pharmacology 2000, 59, 1023-1031. 
64. Holtzheimer P. E. and Nemeroff C. B. Emerging treatments for 
depression. Expert Opinion on Pharmacotherapy 2006, 7, 2323-2339. 
65. Ramsay R. R. Substrate regulation of monoamine oxidases. J Neural 
Transm Suppl 1998, 52, 139-47. 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
44 
 
66. Abeles R. H. Suicide enzyme inactivators. Basic Life Sci 1983, 25, 287-
305. 
67. Knoll J., Ecseri Z., Kelemen K., Nievel J. and Knoll B. 
Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch 
Int Pharmacodyn Ther 1965, 155, 154-64. 
68. Magyar K., Vizi E. S., Ecseri Z. and Knoll J. Comparative 
pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-
propinylamine (E-250). Acta Physiol Acad Sci Hung 1967, 32, 377-87. 
69. Finberg J. P., Lamensdorf I., Commissiong J. W. and Youdim M. B. 
Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl 
1996, 48, 95-101. 
70. Palfreyman M. G., McDonald I. A., Bey P., Danzin C., Zreika M. and 
Cremer G. Haloallylamine inhibitors of MAO and SSAO and their therapeutic 
potential. J Neural Transm Suppl 1994, 41, 407-14. 
71. Da Prada M., Kettler R., Keller H. H. and Burkard W. P. Short-lasting 
and reversible inhibition of monoamine oxidase-A by moclobemide. Acta Psychiatr 
Scand Suppl 1990, 360, 103-5. 
72. Bench C. J., Price G. W., Lammertsma A. A., Cremer J. C., Luthra S. K., 
Turton D., Dolan R. J., Kettler R., Dingemanse J., Da Prada M. and et al. Measurement 
of human cerebral monoamine oxidase type B (MAO-B) activity with positron 
emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-
6327. Eur J Clin Pharmacol 1991, 40, 169-73. 
73. Lebreton L., Curet O., Gueddari S., Mazouz F., Bernard S., Burstein C. 
and Milcent R. Selective and potent monoamine oxidase type B inhibitors: 2-
substituted 5-aryltetrazole derivatives. J Med Chem 1995, 38, 4786-92. 
74. Truong D. D., Galloway M. P., Pezzoli G., Jamrozik Z. and Fahn S. 
Milacemide increases 5-hydroxytryptamine and dopamine levels in rat brain--possible 
mechanisms of milacemide antimyoclonic property in the p,p'-DDT-induced 
myoclonus. Pharmacol Biochem Behav 1989, 32, 993-1001. 
75. Santillo A. F., Gambini J. P., Lannfelt L., Langstrom B., Ulla-Marja L., 
Kilander L. and Engler H. In vivo imaging of astrocytosis in Alzheimer's disease: an 
[11C]-L-deuteriodeprenyl and PIB PET study. Eur J Nucl Med Mol Imaging 2011, 38, 
2202-8. 
76. Bergstrom M., Kumlien E., Lilja A., Tyrefors N., Westerberg G. and 
Langstrom B. Temporal lobe epilepsy visualized with PET with [11C]L-deuterium-
deprenyl--analysis of kinetic data. Acta Neurol Scand 1998, 98, 224-31. 
77. Fowler J. S., Logan J., Volkow N. D., Wang G. J., MacGregor R. R. and 
Ding Y. S. Monoamine oxidase: radiotracer development and human studies. Methods 
2002, 27, 263-277. 
78. Fowler J. S., Logan J., Volkow N. D. and Wang G. J. Translational 
neuroimaging: positron emission tomography studies of monoamine oxidase. Mol 
Imaging Biol 2005, 7, 377-87. 
79. Holland J. P., Cumming P. and Vasdev N. PET radiopharmaceuticals for 
probing enzymes in the brain. Am J Nucl Med Mol Imaging 2013, 3, 194-216. 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
45 
 
80. MacGregor R. R., Halldin C., Fowler J. S., Wolf A. P., Arnett C. D., 
Langstrom B. and Alexoff D. Selective, irreversible in vivo binding of [11C]clorgyline 
and [11C]-L-deprenyl in mice: potential for measurement of functional monoamine 
oxidase activity in brain using positron emission tomography. Biochem Pharmacol 
1985, 34, 3207-10. 
81. Fowler J. S., Macgregor R. R., Wolf A. P., Arnett C. D., Dewey S. L., 
Schlyer D., Christman D., Logan J., Smith M., Sachs H., Aquilonius S. M., Bjurling P., 
Halldin C., Hartvig P., Leenders K. L., Lundqvist H., Oreland L., Stalnacke C. G. and 
Langstrom B. Mapping human-brain monoamine oxidase-A  and oxidase-B with C-11 
labeled suicide inactivators and PET. Science 1987, 235, 481-485. 
82. Ishiwata K., Ido T., Yanai K., Kawashima K., Miura Y., Monma M., 
Watanuki S., Takahashi T. and Iwata R. Biodistribution of a positron-emitting suicide 
inactivator of monoamine oxidase, carbon-11 pargyline, in mice and a rabbit. J Nucl 
Med 1985, 26, 630-6. 
83. Hirvonen J., Kailajarvi M., Haltia T., Koskimies S., Nagren K., Virsu P., 
Oikonen V., Sipila H., Ruokoniemi P., Virtanen K., Scheinin M. and Rinne J. O. 
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a 
dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther 
2009, 85, 506-12. 
84. Carter S. F., Scholl M., Almkvist O., Wall A., Engler H., Langstrom B. 
and Nordberg A. Evidence for astrocytosis in prodromal Alzheimer disease provided 
by [11C]-deuterium-L-deprenyl: a multitracer PET paradigm combining [11C]-
Pittsburgh compound B and 18F-FDG. J Nucl Med 2012, 53, 37-46. 
85. Hirata M., Kagawa S., Yoshimoto M. and Ohmomo Y. Synthesis and 
characterization of radioiodinated MD-230254: a new ligand for potential imaging of 
monoamine oxidase B activity by single photon emission computed tomography. Chem 
Pharm Bull (Tokyo) 2002, 50, 609-14. 
86. Plenevaux A., Fowler J. S., Dewey S. L., Wolf A. P. and Guillaume M. 
The synthesis of no-carrier-added DL-4-[18F]fluorodeprenyl via the nucleophilic 
aromatic substitution reaction. Int J Rad Appl Instrum A 1991, 42, 121-7. 
87. Mukherjee J., Yang Z. Y. and Lew R. N-(6-18F-fluorohexyl)-N-
methylpropargylamine: a fluorine-18-labeled monoamine oxidase B inhibitor for 
potential use in PET studies. Nucl Med Biol 1999, 26, 111-6. 
88. Saba W., Valette H., Peyronneau M. A., Bramoulle Y., Coulon C., Curet 
O., George P., Dolle F. and Bottlaender M. [11C]SL25.1188, a new reversible 
radioligand to study the monoamine oxidase type B with PET: preclinical 
characterisation in nonhuman primate. Synapse 2010, 64, 61-9. 
89. Blauenstein P., Remy N., Buck A., Ametamey S., Haberli M. and 
Schubiger P. A. In vivo properties of N-(2-aminoethyl)-5-halogeno-2-
pyridinecarboxamide 18F- and 123I-labelled reversible inhibitors of monoamine oxidase 
B. Nucl Med Biol 1998, 25, 47-52. 
90. Beer H. F., Frey L. D., Haberli M. and Schubiger P. A. [123I/18F] N-(2-
aminoethyl)-5-halogeno-2-pyridinecarbox-amides, site specific tracers for MAO-B 
mapping with SPECT and PET. Nucl Med Biol 1995, 22, 999-1004. 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
46 
 
91. Fowler J. S., Wang G. J., Logan J., Xie S., Volkow N. D., MacGregor R. 
R., Schlyer D. J., Pappas N., Alexoff D. L., Patlak C. and et al. Selective reduction of 
radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl 
and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med 1995, 36, 1255-62. 
92. Halldin C., Bjurling P., Stalnacke C. G., Jossan S. S., Oreland L. and 
Langstrom B. [11C]labelling of dimethylphenethylamine in two different positions and 
biodistribution studies. Int J Rad Appl Instrum A 1989, 40, 557-60. 
93. Park B. K. and Kitteringham N. R. Effects of fluorine substitution on 
drug metabolism: pharmacological and toxicological implications. Drug Metab Rev 
1994, 26, 605-43. 
94. Le Bars D. Fluorine-18 and medical imaging: Radiopharmaceuticals for 
positron emission tomography. J Fluor Chem 2006, 127, 1488-1493. 
95. Hagmann W. K. The many roles for fluorine in medicinal chemistry. J 
Med Chem 2008, 51, 4359-69. 
96. Schlyer D. J. Production of radionuclides in accelerators, in Welch MJ, 
Redvanley CS (eds): Handbook of Radiopharmaceuticals, Radiochemistry and 
Applications. New York, John Wiley & Sons Inc 2003. 
97. Bergman J. and Solin O. Fluorine-18-labeled fluorine gas for synthesis of 
tracer molecules. Nucl Med Biol 1997, 24, 677-83. 
98. Teare H., Robins E. G., Kirjavainen A., Forsback S., Sandford G., Solin 
O., Luthra S. K. and Gouverneur V. Radiosynthesis and evaluation of [18F]Selectfluor 
bis(triflate). Angew Chem Int Ed Engl 2010, 49, 6821-4. 
99. Satyamurthy N., Bida G. T., Phelps M. E. and Barrio J. R. N-[18F]fluoro-
N-alkylsulfonamides: novel reagents for mild and regioselective radiofluorination. Int J 
Rad Appl Instrum A 1990, 41, 733-8. 
100. Gallagher B. M., Ansari A., Atkins H., Casella V., Christman D. R., 
Fowler J. S., Ido T., MacGregor R. R., Som P., Wan C. N., Wolf A. P., Kuhl D. E. and 
Reivich M. Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a 
radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: 
tissue distribution and imaging studies in animals. J Nucl Med 1977, 18, 990-6. 
101. Levy S., Elmaleh D. R. and Livni E. A new method using anhydrous 
[18F]fluoride to radiolabel 2-[18F]fluoro-2-deoxy-D-glucose. J Nucl Med 1982, 23, 918-
22. 
102. Namavari M., Bishop A., Satyamurthy N., Bida G. and Barrio J. R. 
Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: a high 
yield synthesis of 6-[18F]Fluoro-L-dopa. Int J Rad Appl Instrum A 1992, 43, 989-96. 
103. Schlyer D. J., Firouzbakht M. L. and Wolf A. P. Impurities in the 
[18O]water target and their effect on the yield of an aromatic displacement reaction with 
[18F]fluoride. Appl Radiat Isot 1993, 44, 1459-65. 
104. Schlyer D. J. PET tracers and radiochemistry. Ann Acad Med Singapore 
2004, 33, 146-54. 
105. Gomzina N. A., Vasil'ev D. A. and Krasikova R. N. Optimization of 
Automated Synthesis of 2-[18F]Fluoro-2-deoxy-D-glucose Involving Base Hydrolysis. 
Radiochemistry 2002, 44, 403-409. 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
47 
 
106. Block D., Klatte B., Knochel A., Beckmann R. and Holm U. NCA F-18 
labeling of aliphatic compounds in high yields via aminopolyether-supported 
nucleophilic substitution. J Label Com Radio 1986, 23, 467-477. 
107. Hamacher K., Coenen H. H. and Stocklin G. Efficient stereospecific 
synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether 
supported nucleophilic substitution. J Nucl Med 1986, 27, 235-8. 
108. Kim D. W., Ahn D. S., Oh Y. H., Lee S., Kil H. S., Oh S. J., Lee S. J., 
Kim J. S., Ryu J. S., Moon D. H. and Chi D. Y. A new class of SN2 reactions catalyzed 
by protic solvents: Facile fluorination for isotopic labeling of diagnostic molecules. J 
Am Chem Soc 2006, 128, 16394-7. 
109. Kim D. W., Jeong H. J., Lim S. T., Sohn M. H., Katzenellenbogen J. A. 
and Chi D. Y. Facile nucleophilic fluorination reactions using tert-alcohols as a reaction 
medium: significantly enhanced reactivity of alkali metal fluorides and improved 
selectivity. J Org Chem 2008, 73, 957-62. 
110. Lee S. J., Oh S. J., Chi D. Y., Kang S. H., Kil H. S., Kim J. S. and Moon 
D. H. One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic 
solvent system. Nucl Med Biol 2007, 34, 345-51. 
111. Ametamey S. M., Honer M. and Schubiger P. A. Molecular imaging with 
PET. Chem Rev 2008, 108, 1501-16. 
112. Kilbourn M. R. Fluorine-18 labeling of radiopharmaceuticals. Nuclear 
Science Series 1990, NAS-NS3203, National Academy Press, Washington, D.C. 
113. Dolle F. Fluorine-18-labelled fluoropyridines: Advances in 
radiopharmaceutical design. Current Pharmaceutical Design 2005, 11, 3221-3235. 
114. Angelini G., Speranza M., Wolf A. P. and Shiue C. Y. Nucleophilic 
aromatic-substitution of activated cationic groups by F-18-labeled fluoride - A useful 
route to no-carrier-added (NCA) F-18-labeled aryl fluorides. J Fluor Chem 1985, 27, 
177-191. 
115. Carroll M. A., Pike V. W. and Widdowson D. A. New synthesis of 
diaryliodonium sulfonates from arylboronic acids. Tetrahedron Letters 2000, 41, 5393-
5396. 
116. Weissbach H., Smith T. E., Daly J. W., Witkop B. and Udenfriend S. A 
rapid spectrophotometric assay of mono-amine oxidase based on the rate of 
disappearance of kynuramine. J Biol Chem 1960, 235, 1160-3. 
117. Hall H., Halldin C., Farde L. and Sedvall G. Whole hemisphere 
autoradiography of the postmortem human brain. Nucl Med Biol 1998, 25, 715-9. 
118. Schou M., Halldin C., Pike V. W., Mozley P. D., Dobson D., Innis R. B., 
Farde L. and Hall H. Post-mortem human brain autoradiography of the norepinephrine 
transporter using (S,S)-[18F]FMeNER-D2. Eur Neuropsychopharmacol 2005, 15, 517-
20. 
119. Gulyas B., Makkai B., Kasa P., Gulya K., Bakota L., Varszegi S., 
Beliczai Z., Andersson J., Csiba L., Thiele A., Dyrks T., Suhara T., Suzuki K., Higuchi 
M. and Halldin C. A comparative autoradiography study in post mortem whole 
hemisphere human brain slices taken from Alzheimer patients and age-matched 
controls using two radiolabelled DAA1106 analogues with high affinity to the 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
48 
 
peripheral benzodiazepine receptor (PBR) system. Neurochemistry International 2009, 
54, 28-36. 
120. Clark J. D., Gebhart G. F., Gonder J. C., Keeling M. E. and Kohn D. F. 
Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR J 
1997, 38, 41-48. 
121. Karlsson P., Farde L., Halldin C., Swahn C. G., Sedvall G., Foged C., 
Hansen K. T. and Skrumsager B. PET examination of [11C]NNC 687 and [11C]NNC 
756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl) 
1993, 113, 149-56. 
122. Varrone A., Sjoholm N., Eriksson L., Gulyas B., Halldin C. and Farde L. 
Advancement in PET quantification using 3D-OP-OSEM point spread function 
reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 2009, 36, 1639-50. 
123. Knoll J. Critical role of MAO inhibition in Parkinson's disease. Adv 
Neurol 1987, 45, 107-10. 
124. Fowler C. J. and Ross S. B. Selective inhibitors of monoamine oxidase A 
and B: biochemical, pharmacological, and clinical properties. Med Res Rev 1984, 4, 
323-58. 
125. Effects of tocopherol and deprenyl on the progression of disability in 
early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993, 328, 176-
83. 
126. Fowler J. S., Logan J., Wang G. J., Volkow N. D., Telang F., Ding Y. S., 
Shea C., Garza V., Xu Y. W., Li Z. H., Alexoff D., Vaska P., Ferrieri R., Schlyer D., 
Zhu W. and Gatley S. J. Comparison of the binding of the irreversible monoamine 
oxidase tracers, [11C]clorgyline and [11C]l-deprenyl in brain and peripheral organs in 
humans. Nuclear Medicine and Biology 2004, 31, 313-319. 
127. Metro T. X., Appenzeller J., Pardo D. G. and Cossy J. Highly 
enantioselective synthesis of beta-amino alcohols. Org Lett 2006, 8, 3509-3512. 
128. Arnett C. D., Fowler J. S., MacGregor R. R., Schlyer D. J., Wolf A. P., 
Langstrom B. and Halldin C. Turnover of brain monoamine oxidase measured in vivo 
by positron emission tomography using L-[11C]deprenyl. J Neurochem 1987, 49, 522-7. 
129. Shin H. S. Metabolism of selegiline in humans - Identification, excretion, 
and stereochemistry of urine metabolites. Drug Metabolism and Disposition 1997, 25, 
657-662. 
130. Cumming P., Yokoi F., Chen A., Deep P., Dagher A., Reutens D., 
Kapczinski F., Wong D. F. and Gjedde A. Pharmacokinetics of radiotracers in human 
plasma during positron emission tomography. Synapse 1999, 34, 124-34. 
131. Reynolds G. P., Elsworth J. D., Blau K., Sandler M., Lees A. J. and Stern 
G. M. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J 
Clin Pharmacol 1978, 6, 542-4. 
132. Yoshida T., Yamada Y., Yamamoto T. and Kuroiwa Y. Metabolism of 
deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of 
metabolism to MAO-B inhibitory potency. Xenobiotica 1986, 16, 129-36. 
133. Stocchi F., Vacca L., Grassini P., De Pandis M. F., Battaglia G., Cattaneo 
C. and Fariello R. G. Symptom relief in Parkinson disease by safinamide: Biochemical 
Development of Novel Fluorine-18 labeled PET Radioligands for Monoamine Oxidase B (MAO-B) 
 
49 
 
and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006, 67, S24-
9. 
134. Bar Am O., Amit T. and Youdim M. B. Contrasting neuroprotective and 
neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and 
selegiline. Neurosci Lett 2004, 355, 169-72. 
135. Bar-Am O., Amit T. and Youdim M. B. Aminoindan and 
hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert 
neuroprotective properties in vitro. J Neurochem 2007, 103, 500-8. 
136. Couty F., Durrat F. and Prim D. Expeditive synthesis of homochiral fused 
tri- and tetrazoles-piperazines from beta-amino alcohols. Tetrahedron Letters 2004, 45, 
3725-3728. 
137. Bowen R. D., Harrison A. G. and Reiner E. J. Ion-dipole complexes in 
the unimolecular reactions of isolated organic ions-effect of N-methylation on olefin 
and amine loss from protected aliphatic-amines. Journal of the Chemical Society-
Perkin Transactions 2 1988, 1009-1013. 
138. Melander L. and Saunders W. H. J. Reaction Rates of lsotopic Molecules. 
John Wiley and Sons, New York 1980. 
139. Yu P. H., Barclay S., Davis B. and Boulton A. A. Deuterium isotope 
effects on the enzymatic oxidative deamination of trace amines. Biochem Pharmacol 
1981, 30, 3089-94. 
140. Fowler J. S., Wolf A. P., MacGregor R. R., Dewey S. L., Logan J., 
Schlyer D. J. and Langstrom B. Mechanistic positron emission tomography studies: 
demonstration of a deuterium isotope effect in the monoamine oxidase-catalyzed 
binding of [11C]L-deprenyl in living baboon brain. J Neurochem 1988, 51, 1524-34. 
141. Logan J., Fowler J. S., Volkow N. D., Wang G. J., MacGregor R. R. and 
Shea C. Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl 
([11C]L-deprenyl-D2) binding in the human brain. Nucl Med Biol 2000, 27, 43-9. 
142. Davister M. and Locht R. The dissociative ionisation of C2H2 and C2D2-
the CH(CD) (+) dissociation channel – the H(D)C-C(D)H binding-energy. Chemical 
Physics 1995, 191, 333-346. 
143. Fowler J. S., Wang G. J., Logan J., Xie S., Volkow N. D., Macgregor R. 
R., Schlyer D. J., Pappas N., Alexoff D. L., Patlak C. and Wolf A. P. Selective 
reduction of radiotracer trapping by deuterium substitution – comparison of carbon-11-
L-deprenyl and carbon-11-L-deprenyl-D2 for MAO-B mapping   J Nucl Med 1995, 36, 
1255-1262. 
144. Johansson A., Engler H., Blomquist G., Scott B., Wall A., Aquilonius S. 
M., Langstrom B. and Askmark H. Evidence for astrocytosis in ALS demonstrated by 
[11C](L)-deprenyl-D2 PET. J Neurol Sci 2007, 255, 17-22. 
145. Dolle F., Bramoulle Y., Hinnen F. and Fowler J. S. Efficient synthesis 
and formulation of (R)-(-)- C-11 Deprenyl, a selective radioligand for the quantification 
of MAO-B activity using PET. J Label Com Radio 2002, 45, 803-811. 
146. Kalasz H., Bartok T., Komoroczy R., Szoko E., Haberle D., Kiss J. P., 
Hennings E. C. P., Magyar K. and Furst S. Analysis of deprenyl metabolites in the rat 
brain using HPLC-ESMS. Curr Med Chem 1999, 6, 271-278.  
